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Breast cancer is the most common malignancy affecting females globally. Hereditary breast and ovarian cancer 
(HBOC) syndrome is caused by pathogenic variants in BRCA1 and BRCA2 and is seen in approximately 50% of 
families with a strong history of breast and ovarian cancers. Predictive testing (PT) is offered to unaffected 
individuals with a positive family history of HBOC, with an already identified BRCA1 or BRCA2 mutation in an 
affected family member. There is an overwhelming amount of research that has focused on the after-effects of 
diagnostic genetic testing for HBOC but there has been little investigation into how individuals experience the 
actual PT process. The present study therefore aimed to investigate individuals’ decisions for undergoing and 
their experiences of PT for HBOC in a local context, by focusing on at-risk South African individuals residing in the 
Western Cape Province.  
Sixteen participants were recruited retrospectively from the breast cancer and/or clinical genetics clinics at 
Groote Schuur Hospital, Tygerberg Hospital and private genetic counselling practices in Cape Town. Semi-
structured interviews were conducted, and the interview transcripts were analysed using the framework 
approach for qualitative data analysis. Using this approach, five themes were identified relating to the 
perspectives and experiences of individuals undergoing PT for HBOC, in selected settings in the Western Cape.  
While some participants felt that their decision to pursue PT was influenced by their family history of cancer and 
the associated cancer-related distress, others felt that their decision was made out of a sense of duty to their 
families or in solidarity with those that were affected or received a positive test result. Overall, the participants 
felt that the pre-test counselling was beneficial in allowing for an improved understanding of HBOC, however 
not all participants felt that the pre-test counselling prepared them for receiving their results. Receiving a 
negative test result was often accompanied by feelings of guilt and did not exempt participants from the fear of 
developing cancer. Some of the concerns raised by participants that received a positive test result were centred 
around prophylactic intervention and its effect on body image. Overall, participants felt empowered by their 
mutation status and felt that they were better able to manage their risk. The need for additional support, both 
practical and emotional support, was particularly evident amongst mutation-carriers. The findings of this study 
provide valuable insight into the perspectives and experiences of this population, which could potentially impact 
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CHAPTER 1: INTRODUCTION 
1.1 CHAPTER INTRODUCTION 
The first chapter outlines (1) breast cancer epidemiology, (2) the genetic aetiology of hereditary breast and 
ovarian cancer, (3) cancer risk associated with BRCA1 and BRCA2, (4) BRCA1 and BRCA2 testing, and (5) 
management and surveillance options.  
Literature was searched for using the Google Scholar and PubMed databases, using the following search terms: 
breast cancer, ovarian cancer, hereditary, BRCA1, BRCA2, genetics, genetic counselling, family, predictive testing, 
as well as permutations of these terms. As this is not a systematic literature review, the most informative 
literature was selected to present the background and rationale for this study.  
1.2 EPIDEMIOLOGY OF BREAST CANCER 
The global burden of non-communicable diseases continues to rise, with some of the contributing factors being 
increased lifespan, lifestyle changes and prolonged exposure to risk factors. Cancer is identified globally as one 
of the most important diseases. From an epidemiologic standpoint, cancer is particularly complex due to it being 
a multifactorial condition (Ghoncheh, Pournamdar & Salehiniya, 2016). It is a complex and heterogeneous 
disease with respect to the cellular origin, histology, disease progression, metastatic potential, mutations, 
response to therapeutics and overall clinical outcome (Cetin & Topcul, 2014). There are several risk factors that 
are recognised as being associated with the development of breast cancer. These include hormonal risk factors 
such as oestrogen and progesterone exposure, reproductive and obesity risk factors, as well as the role that the 
inheritance of highly penetrant high-risk genes play, amongst others (Cetin & Topcul, 2014). 
Breast cancer is the most common malignancy affecting women globally (Seymour, et al. 2016). The cumulative 
incidence of breast cancer in developed countries suggests that approximately 1 in 10 females will develop breast 
cancer by the age of 70 years, and that there is a lifetime risk of approximately 10-12% (Schoeman, et al. 2013; 
Lalloo & Evans, 2012). Although the incidence of breast cancer is greater in developed countries, breast cancer-
related death is higher in developing countries (Ghoncheh, Pournamdar & Salehiniya, 2016).  
As in developed countries, breast cancer is the most prevalent cancer affecting females in South Africa (SA) 
(Schlebusch, et al. 2010). The incidence of breast and ovarian cancer in SA varies by time, location and ethnic 
group; however, there is supporting evidence to suggest that the incidence of breast cancer has increased over 
time (Hoffman, et al. 2000; NCR, 2011). Breast cancer accounts for approximately 22% of all cancers diagnosed 




due to delayed diagnosis (Murray, 2003; Walker, et al. 2004). Recent local estimates indicate that the lifetime 
risks of developing breast and ovarian cancer for women in SA are 1 in 26 and 1 in 391, respectively.  
1.3 GENETICS OF HBOC 
Approximately 5-10% of breast cancer has a strongly heritable component (Claus, Risch & Thompson, 1991; 
Newman, et al. 1988). Of all cancers, 4-5% are due to the transmission of Mendelian genes that are highly 
penetrant, in an autosomal dominant inheritance pattern (Fackenthal & Olopade, 2007; Lalloo & Evans, 2012). 
Two high penetrance genes, Breast Cancer Gene 1 (BRCA1) and Breast Cancer Gene 2 (BRCA2) are most 
frequently (~50% of inherited breast cancers) identified as monogenic causes for hereditary breast and/or 
ovarian cancers. However pathogenic variants in these genes are responsible for a small proportion of breast 
cancer cases, approximately 2%, and ovarian cancer cases overall (Lalloo & Evans, 2012). Despite being the 
minority, these cases are of particular importance. Individuals who carry a pathogenic variant in BRCA1 or BRCA2 
are often described as having hereditary breast and ovarian cancer (HBOC) syndrome (Schoeman, et al. 2013; 
Seymour, et al. 2016).  
As these names suggest, BRCA1 and BRCA2 mutations, in addition to breast cancer, confer an increased risk for 
ovarian cancer in females. Pathogenic variants in these genes are known to increase the risk of developing breast 
and ovarian cancer in women and breast and prostate cancer in men (Lalloo & Evans, 2012), amongst others 
detailed in section 1.4. The identification of the BRCA1 gene in 1990 and the BRCA2 gene in 1995, and the 
subsequent availability of predictive testing (PT), has afforded unaffected individuals with a family history of 
HBOC the opportunity to determine if they carry the mutation (Claes, et al. 2003). Consequently, inherited forms 
of breast and ovarian cancer have both a clinical and public health significance. 
In some countries, such as SA, founder mutations have been identified in certain population groups and account 
for a significant proportion of BRCA1 and BRCA2 mutations locally (Seymour, et al. 2016). To date, three founder 
mutations have been identified in the Afrikaner population group, three in the Ashkenazi Jewish population 
group, one in the mixed ancestry and one in the Xhosa population groups (Schoeman, et al. 2013; Seymour, et 
al. 2016). Testing for founder mutations is based on specific institutional criteria and varies from one institution 
to the next.  
Other than age, a positive family history is the strongest known factor associated with an increased risk for 
developing breast cancer. As the number of relatives affected with breast cancer increases, an individual’s risk 
of developing breast cancer also increases. A woman’s risk is approximately doubled by having one affected first-




developing breast cancer together with the chance that there could be a hereditary component to the family’s 
risk, thereby highlighting the importance of obtaining a comprehensive family history (Lalloo & Evans, 2012). 
Factors suggesting there is a familial susceptibility gene include a large number of affected individuals with 
breast, ovarian, or prostate cancer on one side of the family, a young average age at which these cancers were 
diagnosed, more than one primary cancer in one individual with an early age of onset, and the association of 
breast cancer with other related cancers in a family. These include early onset prostate cancer in male relatives 
and ovarian cancer in female relatives (Lalloo & Evans, 2012). The level of risk assessed can then be used to 
determine the subsequent testing and management options that are available to the individual and other at-risk 
family members (Lalloo & Evans, 2012).  
Women at risk of developing breast cancer often require advice about their risk and how to be proactive when 
faced with this risk (Lalloo & Evans, 2012). This can be challenging when there is a limited amount of family 
history information available. Some studies have identified that the concept of cancer may be unfamiliar to some 
patients, therefore the communication between family members regarding the cause of death of an affected 
family member may not necessitate the knowledge of the type of cancer (De Vos, et al. 1999; Schoeman, et al. 
2013; Walker, et al. 2004). 
1.4 CANCER RISK ASSOCIATED WITH BRCA1 AND BRCA2 
BRCA1 and BRCA2 are large genes that are expressed in several tissues, including breast and ovarian tissue. The 
proteins that are encoded by both BRCA1 and BRCA2 appear to have similar functions, justifying why mutations 
in these genes result in a similar and specific hereditary predisposition to breast and ovarian malignancies (Godet 
& Gilkes, 2017). Both genes function as tumour suppressor genes and are believed to be involved in transcription 
regulation and DNA repair. BRCA1 also functions in regulating cell cycle progression and checkpoint control 
(Schlebusch, et al. 2010). Both genes are functionally recessive, meaning that both copies of the allele must be 
mutated in the cell for breast, ovarian or other associated cancers to develop (Godet & Gilkes, 2017). 
Cells that possess germline mutations in BRCA1 or BRCA2 are vulnerable to DNA damage, which is a crucial 
feature in the progression of cancer formation (Kurian, 2010). Pathogenic variants in BRCA1 and BRCA2 each 
account for approximately 10% of hereditary forms of breast cancer. A summary of the cancer risks associated 
with germline pathogenic variants in BRCA1 and BRCA2 are detailed in table 1 below (Lee, Higgins & Qureshi, 
2015; Petrucelli, Daly & Pal, 2016).  
Table 1: Summary of lifetime cancer risks associated with pathogenic variants in BRCA1 and BRCA2 
Cancer type  BRCA1 BRCA2 




Ovarian cancer  39-63% 16.5-27% 
Second primary breast cancer 83% by age 70 62% by age 70 
Male breast cancer  ~1% 5-10% 
Prostate cancer  - 14-20% 
Pancreas, biliary tree, stomach or melanoma  <1 in 20  
In cases where there are multiple family members affected, the risk estimates at the upper end of the ranges 
displayed in table 1 are likely to be appropriate as a result of the co-inheritance of possible modifier genes and 
shared environmental exposures. There is also an increased risk of contralateral breast cancer in affected 
carriers, the highest being with the age of diagnosis being less than 40 years. This risk then decreases as the age 
of first diagnosis increases (Firth & Hurst, 2017). Ovarian cancer risks in BRCA2 carriers are low before the age of 
50 years. Importantly, breast cancer displays incomplete penetrance amongst BRCA1 and BRCA2 mutation 
carriers. Other factors such as age and gender, as well as nongenetic factors play an important role in developing 
breast cancer (Godet & Gilkes, 2017).  
1.5 BRCA1 AND BRCA2 TESTING 
According to Tygerberg Hospital (TBH) criteria, individuals who have been diagnosed with breast or ovarian 
cancer together with at least one first-degree relative with breast cancer at an age younger than 50 years or 
ovarian cancer at any age, or male breast cancer in a relative meet the family history criteria required to undergo 
full BRCA1 and BRCA2 screening in order to determine the cause of their cancer (Schoeman, et al. 2013). Testing 
for local founder mutations may be offered following appropriate risk analysis (Schoeman, et al. 2013).  However, 
these guidelines may differ according to setting and across different clinical institutions. The criteria that is used 
to assess whether an individual is eligible to pursue full BRCA1 and BRCA2 screening or founder mutation testing 
also varies across different clinical institutions. These criteria are determined based on the availability of funding 
and the likelihood (10%) of identifying a pathogenic variant.  
While some settings base this decision on family history and the relation of the proband to an affected family 
member, others may use scoring systems such as the Manchester Scoring System or the Breast and Ovarian 
Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) risk assessment model to determine 
the likelihood of identifying a BRCA1 or BRCA2 mutation in the proband (Evans, et al. 2017; Lim, Borje & Allen, 
2017).  At Groote Schuur Hospital (GSH), individuals with a Manchester score of 15 or greater meet criteria to 
undergo full BRCA1 and BRCA2 screening.  Founder mutation testing may be offered to individuals that come 




As a first-line testing option, individuals are offered testing for population-specific founder mutations, if 
appropriate. Additional molecular testing, including full BRCA1 and BRCA2 sequencing and analysis of large 
rearrangements, may be offered to individuals with a negative founder mutation result, should the family and 
clinical history warrant it (Seymour, et al. 2016). As genetic testing becomes routinely incorporated into the 
management of women diagnosed with breast and/or ovarian cancer and individuals who are at an increased 
risk for these diseases, it is important to take into account that mutations in other cancer susceptibility genes 
may contribute to an increased breast cancer risk. Therefore, there may be mutation carriers with less common 
high- and moderate-penetrance cancer susceptibility genes. Less is known about the management of these 
individuals when compared to BRCA1 and BRCA2 mutation carriers (Graffeo, et al. 2016). More recently, germline 
multigene panels have been used as a first-line testing option for individuals diagnosed with breast and ovarian 
cancer, however there is still limited availability of this option in the South African public sector. As with the 
eligibility criteria, these testing options may also vary across different institutions.   
Since 2005 there has been a breast cancer genetic service in the Western Cape Province of SA which offers 
genetic testing for BRCA1 and BRCA2 mutations. Despite international institutions having established guidelines 
for the genetic counselling and testing process, there are still significant challenges (Robson, et al. 2010). In SA, 
although there is a lack of established guidelines, similar challenges arise. The local population comprises of 
diverse ethno-linguistic groups, with isiXhosa being the predominant one. White individuals of Afrikaner and 
non-Afrikaner ancestry and indigenous black South Africans each constitute a quarter of the population, while 
individuals of mixed ancestry constitute approximately half of the population (Schoeman, et al. 2013). 
Formal South African guidelines have not yet been established to assist genetic counsellors in determining 
whether the analysis of founder mutations identified in a specific population group is sufficient or whether it is 
essential to pursue additional molecular analysis following a negative result (Seymour, et al. 2016). Unless full 
sequencing of BRCA1 and BRCA2 has been performed, a negative test result should be considered as being 
uninformative and not that there are no genetic mutations predisposing the individual to HBOC (Lalloo & Evans, 
2012). The mutations in these genes may have simply been missed by the methods employed (Schlebusch, et al. 
2010).  
The isolation and identification of BRCA1 and BRCA2 has afforded individuals who are at an increased risk for 
developing HBOC the opportunity to learn whether they carry a risk-conferring mutation (Lerman, et al. 1998). 
Affected individuals who have tested positive for a BRCA1 or BRCA2 mutation are encouraged to inform all at-
risk adult relatives about HBOC and to notify them of the possibility of undergoing PT to identify the familial 




increased number of women undergoing genetic testing to determine if they are at an increased risk of 
developing breast and ovarian cancer. This has been described in the media as the ‘Angelina Jolie effect’ (McCrea 
& McCutcheon, 2017).  
PT is offered to unaffected individuals with a positive family history of HBOC with an already identified BRCA1 or 
BRCA2 mutation in an affected family member. These individuals are at 50% risk to have inherited the familial 
mutation conferring an increased susceptibility to cancer. It has been recommended that this be performed in a 
clinical setting as part of a genetic testing program (Seymour, et al. 2016). The delivery of genetic counselling 
plays an important role for at-risk individuals and their families during this time. Genetic counsellors are able to 
provide valuable support for those undergoing PT, guiding individuals through the rigorous decision making 
process and advise them on how best to manage their risk based on established clinical recommendations 
(McCrea & McCutcheon, 2017).  
1.6 MANAGEMENT AND SURVEILLANCE OPTIONS FOR BRCA1 AND BRCA2 CARRIERS 
An individual’s BRCA1 or BRCA2 mutation status provides valuable insights with regard to prevention and 
treatment options (Godet & Gilkes, 2017). HBOC poses a considerable health burden on at-risk individuals and 
populations as a result of the significantly increased lifetime risks of developing breast and ovarian cancer. This 
can be greatly reduced through appropriate surveillance or prevention behaviours (Buchanan, et al. 2017). 
Management options for mutation carriers, both affected and unaffected, include regular surveillance, 
prophylactic surgery, such as risk-reducing bilateral mastectomy (RRBM) and/or bilateral salpingo-
oophorectomy (BSO), prophylactic medication and risk avoidance (Lalloo & Evans, 2012). The significantly 
increased breast cancer risk can be reduced by more than 90% with the uptake of a RRBM and by approximately 
50% with the uptake of BSO in pre-menopausal women. A BSO can reduce the risk of ovarian cancer by 80-90% 
(Gilbert, et al. 2017; Hartmann, et al. 2001; Kauff, et al. 2008).  
Breast cancer surveillance is available to women who are carriers of a risk-conferring mutation in BRCA1 or BRCA2 
as well as their first-degree relatives. Surveillance recommendations are diverse and vary from one institution to 
the next. With the appropriate management and surveillance, mutation carriers have the opportunity to detect 
or prevent cancer at early stages when there is an increased likelihood for successful treatment outcomes (Godet 
& Gilkes, 2017). Many surveillance programs start before the age of 30 years and include annual clinical breast 
examination, breast magnetic resonance imaging (MRI), annual mammography screening and breast 




Mammography aids in detecting in situ carcinomas that may not be visible in MRI images. Early detection of 
malignancy is important for women with BRCA1 or BRCA2 mutations as they are more likely to develop more 
aggressive forms of breast cancer (van Zelst, et al. 2017). Some surveillance options, such as mammography 
screening and MRI, are limited in their ability to detect the disease early enough or to prevent the disease (Lalloo 
& Evans, 2012). Risk avoidance activities that could be undertaken include smoking cessation, reduced caloric 
intake, avoiding obesity, increased physical activity, avoiding exposure to carcinogens and attendance of regular 
heath check-ups (Agnihotri, et al. 2014).  
1.7 CHAPTER SUMMARY   
In this chapter breast cancer is introduced, both epidemiologically and within the context of SA. The genetics of 
HBOC are discussed in detail and the cancer risks associated with mutations in BRCA1 and BRCA2 are described. 
The testing options for BRCA1 and BRCA2 are explored and addressed in a South African context. Management 
and surveillance options are introduced. In the next chapter, PT for HBOC is presented as it provides a rationale 





CHAPTER 2: PREDICTIVE TESTING FOR HBOC 
2.1 CHAPTER INTRODUCTION  
In this chapter, PT for HBOC is outlined. In particular, (1) the complexities of PT, (2) the psychosocial challenges 
related to HBOC, and (3) the role of pre-test counselling in PT for HBOC. The rationale for this study will be 
contextualised prior to introducing the aim and objectives of this study.  
2.2 PREDICTIVE TESTING IN SA 
There is a considerable lack of specialised clinical services in SA. One area in which this is particularly evident is 
genetic services. With only three urban centres in the country that offer a fully integrated genetic service, 
including clinical, diagnostic and genetic counselling services, and two centres that offer clinical genetic services 
with some laboratory support, the lack of genetics professionals results in a significant proportion of the South 
African population not having access to the appropriate genetic services. These services are aimed at assisting 
individuals whose lives may be affected by a disorder with a significant hereditary component (Beighton, et al. 
2012).  
In a South African context, very little is understood about how effective the PT process is at preparing individuals 
for receiving their test results and how family members who are found to have a BRCA1 or BRCA2 mutation use 
the knowledge of their status (Schoeman, et al. 2013). The PT process in SA typically involves pre-test counselling, 
molecular genetic testing and post-test counselling during which the results are returned to the individual. In 
most cases, pre-test counselling of individuals undergoing PT is carried out by a genetic counsellor or a suitably 
trained healthcare professional. These individuals are uniquely positioned to obtain a comprehensive family 
history and focus on the individualised needs of the person, while providing tailored information in a supportive 
environment. Pre-test counselling aims to establish a foundation for a discussion pertaining to the information 
about the condition, genetic concepts, inheritance patterns, the DNA test and the testing process. The primary 
focus of pre-test counselling is to assist at-risk individuals in taking the necessary time to work through the pre-
test information in order to facilitate informed decision-making about pursuing PT and to explore the emotional 
impact of all possible testing outcomes (Arning, et al. 2015). 
2.2.1 THE COMPLEXITIES OF PREDICTIVE TESTING  
PT differs in fundamental ways from traditional forms of genetic testing that have been used solely for diagnostic 
purposes. PT aims to identify asymptomatic individuals, that are at an increased risk for a specific disease, early 




screening, surveillance and prevention behaviours. Despite having considerable potential for accurate risk 
assessment, the clinical utility of PT for different conditions is variable (Evans, Skrzynia & Burke, 2001).  
Conventional diagnostic testing has important implications and benefits for family members that are at risk for 
having inherited the pathogenic variant. One of the uncertainties associated with PT, in general, is that the 
outcome of the result is unable to determine whether the condition will develop, by what age it will develop or 
the severity of the condition (Claes, et al. 2005; Evans, Skrzynia & Burke, 2001). However, the benefit of 
individuals knowing their mutation status lies in their ability to take proactive steps towards reducing their risk 
and being in a position to detect cancer early enough to allow for better health outcomes. 
For Huntington disease (HD), a positive predictive test indicates with certainty that the individual will develop 
the condition, but there is still a component of uncertainty about when it will appear and the severity of the 
phenotype. In addition, the interventions that are available to individuals at risk are often recommendations that 
are made on the presumed benefit and not always based on tested outcomes. Individuals are often misconstrued 
into believing that the genetic risk obtained from PT is highly predictable and determinant of disease outcomes. 
These inherent uncertainties are a limitation for PT (Evans, Skrzynia & Burke, 2001).  
PT for HBOC is useful to identify individuals that are at an increased risk for developing cancer but the utility of 
the testing has several limitations (Evans, Skrzynia & Burke, 2001). There is great uncertainty about the predictive 
value of the testing, with penetrance estimates for breast cancer in women ranging from approximately 40-85% 
and ovarian cancer ranging from approximately 30-60% (Lalloo & Evans, 2012). Female mutation carriers may 
develop breast or ovarian cancer, or neither or both, and the age at which cancer develops is largely variable. 
Environmental effects, genetic modifiers and the nature of a specific mutation are all factors that may further 
contribute to the development of the condition (Claes, et al. 2005; Evans, Skrzynia & Burke, 2001). In cases where 
the PT result is negative, this means that these individuals do not possess the allele conferring an increased risk 
for HBOC in that particular family and their risk is therefore the same as that of the general population (Seymour, 
et al. 2016). 
The utility of PT is further limited when taking into consideration surveillance and prevention strategies. The 
efficacy of starting annual mammography screening between the ages of 25 and 35 years is unknown and due 
to the fact that mammography screening is generally recommended for women over the age of 40 years, 
information pertaining to genetic susceptibility would be less relevant for older women. In addition, routine 
surveillance for ovarian cancer is not available. Consequently, the knowledge of an inherited predisposition for 
HBOC does not result in a clear and uncomplicated solution to reduce risk (Evans, Skrzynia & Burke, 2001). In 




genetic situation (MacLeod, et al. 2014). It is important to tailor pre-test discussions about testing to the 
individual’s needs or preferences and to ensure that they are fully informed about the utility and limitations of 
the testing (Evans, Skrzynia & Burke, 2001).  
Owing to the fact that PT is used to identify exact mutations it is relatively inexpensive and cost effective, 
however medical aid schemes may not always cover these costs and state patients may be charged a portion of 
this testing based on their income (Seymour, et al. 2016). A study by Watson, et al. (2004) explored the 
psychosocial impact of HBOC PT in a multicentre cohort in the United Kingdom. When exploring the topic of 
insurance discrimination amongst female participants, 20% of female mutation carriers reported experiencing 
some form of insurance discrimination after their genetic testing. While some women reported difficulties in 
getting life insurance after testing, most women reported difficulties obtaining health insurance. Some women 
also reported that their insurance premiums had increased following testing (Watson, et al. 2004). This has not 
been investigated in SA.  
2.2.2 PSYCHOSOCIAL CHALLENGES RELATED TO HBOC  
One of the main concerns of doing PT for HBOC in a clinical setting is the possibility of adverse psychological 
effects particularly when patients are confronted with a result that is unexpected or unfavourable (Claes, et al. 
2005). Longitudinal research efforts are essential to evaluate the psychosocial impact of PT (Claes, et al. 2005; 
De Vos, et al. 1999). Research carried out in women with a family history of breast and/or ovarian cancer has 
indicated that women who are most interested in undergoing PT are also the most worried and distressed, and 
are perceived to be the most vulnerable for adverse psychological outcomes (Claes, et al. 2005; Lerman and 
Croyle, 1996). Many studies have investigated variables, other than the genetic testing result, that are associated 
with distress following genetic testing (Claes, et al. 2005; Decruyenaere, et al. 2000a). These variables include 
the test results of siblings, spousal and family support, pre-test distress as well as underestimation of the 
emotional impact of the genetic result. Other studies have focused on the perception of risk and the perceived 
seriousness and controllability of the disease (Claes, et al. 2005; Decruyenaere, et al. 2000a). 
Early detection, surveillance and prevention behaviours have the greatest impact on the associated morbidity 
and mortality for BRCA1 or BRCA2 mutation carriers (Buchanan, et al. 2017). BRCA1 and BRCA2 mutation carriers 
often face difficulties when making decisions regarding the best approach to manage their breast cancer risk. 
They need to decide between screening, undertaking risk reducing surgery or prophylactic treatments such as 
chemoprevention. This decision is often made without clear guidance as to which option is best for them. 
Mutation carriers are likely to misinterpret their lifetime cancer risks and perceive them to be a short-term risk, 




cases mutation carriers can also underestimate their lifetime cancer risk, therefore complicating the meaning of 
being at-risk (Hesse-Biber, 2014).  
Individuals who are found not to carry the familial mutation are alleviated from the unnecessary worry associated 
with the increased risk of breast and/or ovarian cancer and will return to the average population risk for 
breast/ovarian cancer. They do not need to undergo increased surveillance or make a decision about undergoing 
prophylactic surgery, however, they do still have to deal with family members who are at increased risk for cancer 
after testing positive for causative mutations which may have other psychological consequences such as dealing 
with survivor guilt, feeling isolated from positive mutation carriers or being worried about family members that 
carry the mutation (Claes, et al. 2005). 
Women from a breast cancer family are likely to have an increased interest in pursuing genetic testing, 
particularly in cases where the affected persons are first degree relatives (Pasacreta, 2003). Individuals who have 
lost relatives to breast cancer are more likely to seek genetic testing (van der Meer, et al. 2012). Young women 
are more likely to consider genetic testing at a younger age if they have a family member diagnosed with breast 
cancer at a young age (Hesse-Biber, 2014; Brunstrom, Murray & McAllister, 2015).  
Women who know that they are at an increased risk of developing breast cancer may feel that they have a 
responsibility to undergo genetic testing in order to assist them in managing this risk, not only for their own 
benefit but for the benefit of their family members (Brunstrom, Murray & McAllister, 2015; Hallowell, 1999). The 
choice to pursue PT for BRCA1 or BRCA2 may be motivated by factors such as planning for the future or making 
decisions about reproduction. Women may feel strongly about not wanting to transmit such a mutation on to 
their children or be at risk for dying early and leaving their children without a mother. Some women are likely to 
feel that not knowing is not an option, as they would need to know for the benefit of their family members or 
their own future family. The decision is often no longer perceived to be a personal choice, but rather one that is 
made on behalf of their children or future children (Brunstrom, Murray & McAllister, 2015, d’Agincourt-Canning, 
2006).  
Young adults, in particular, may feel that they are less likely to make the decision to pursue PT independently, 
owing to the fact that they are more likely to be emotionally and financially dependent on their family, when 
compared to older adults (Brunstrom, Murray & McAllister, 2015). There is no consensus on the age at which to 
undergo PT. Other factors such as career, relationship status, family history of cancer, familial influence and 
family planning, social support, and the age at which at-risk individuals perceive their cancer risk to be the 





There are a number of factors that may influence an individual’s decision to undergo PT for HBOC. These include 
the removal of uncertainty, empowerment and familial obligations (Brunstrom, Murray & McAllister, 2015). 
Removal of uncertainty refers to the fact that individuals at risk may choose to pursue testing in an attempt to 
eradicate the fear and anxieties of not knowing if they are a mutation carrier and that regardless of the result, it 
would be better than not knowing (Brunstrom, Murray & McAllister, 2015, d’Agincourt-Canning, 2006). By having 
the PT result, individuals may feel better prepared to deal with their risk and take control of their situation, 
achieving an overall sense of empowerment. Having children has been shown to play a significant role in an 
individual’s decision to be tested. Some at-risk individuals may believe that undergoing PT for HBOC is what is 
expected of them based on their family history (Brunstrom, Murray & McAllister, 2015; d’Agincourt-Canning, 
2006).  
When exploring the perceived benefit or advantages of PT for HBOC, studies have shown the counselling process 
to have a positive impact as at-risk individuals have an improved knowledge and awareness about the effects of 
being a BRCA1 or BRCA2 mutation carrier, raising awareness about surveillance and having a positive influence 
on an individual’s health and lifestyle choices (Brunstrom, Murray & McAllister, 2015). Genetic counselling is able 
to ensure that the correct information be provided and that individuals are less reliant on seeking out any 
necessary information themselves, information which may be incorrect and result in unnecessary worry. Genetic 
counselling is also able to assist in improving the accuracy of risk perception and distinguishing individuals that 
are likely to be carriers from those that aren’t (Brunstrom, Murray & McAllister, 2015). In contrast, some 
individuals feel that because of their mutation status, they are forced into making difficult and unexpected 
decisions. Decisions such as deciding when or if to have risk reducing surgery or whether to have children 
(Donnelly, et al. 2013). In some instances, the outcomes of the testing may be unexpected and pre-test anxieties 
are replaced with other anxieties following result delivery (Brunstrom, Murray & McAllister, 2015).  
In light of the fact that PT for HBOC is a relatively complex process with various associated uncertainties as well 
as the possible adverse psychological effects associated with this form of testing, it has been suggested that PT 
for HBOC be offered in a multidisciplinary counselling context (Seymour, et al. 2016). This would include genetic 
counselling and possible psychological counselling, in the case of the patient displaying signs of depression 
and/or psychological distress, prior to mutation analysis. Genetic counselling provides individuals with an 
opportunity to receive information about the condition, how the condition is inherited and the chances of other 
individuals in the family carrying the same genetic mutation. They also receive information regarding the cancer 
risks, the options available for undergoing PT and its associated implications, as well as the available options and 




required to enable the individual to make informed decisions about their genetics and undergoing PT while also 
focusing on individual emotional support (Seymour, et al. 2016).  
2.2.3 THE ROLE OF PRE-TEST COUNSELLING IN PREDICTIVE TESTING FOR HBOC  
It is important that individuals that are eligible for PT are managed in a manner that ensures their ability to make 
well informed decisions regarding their risk and that any psychological distress experienced during this period is 
minimised. Less HBOC-related knowledge and risk awareness is associated with adverse psychological effects 
during PT. Males from HBOC families are less likely to undergo PT owing to their low risk of developing cancer. 
Denial or minimalization of the risks may also contribute to the reduced uptake of PT amongst at-risk males (de 
Wit, et al. 1996; Foster, et al. 2002).  
During pre-test counselling for BRCA1 or BRCA2 mutations, it is important to ensure that the decision to pursue 
testing is not influenced by cancer-related distress alone, but that the individuals are well informed so as to avoid 
individuals making poorly informed and impulsive decisions regarding testing. Concerns related to HBOC need 
to be addressed before undergoing testing. Given the family history, it is natural to expect concerns related to 
the development of cancer but it is important to be aware that some individuals may be more likely to require 
additional psychological support. The increased accessibility of genetic testing necessitates that individuals 
receive comprehensive counselling prior to testing in order to address their concerns, allowing them to make 
well-informed decisions and to support them both medically and psychosocially (Foster, et al. 2002).  
One area that has not yet been fully explored is the extent to which pre-test counselling adequately prepares 
and supports individuals undergoing PT (MacLeod, et al. 2014). It has been suggested that further studies should 
focus on examining both the content and the quality of the counselling interaction during this period (Meiser & 
Halliday, 2002). In a qualitative study exploring the experiences of PT in 36 individuals younger than the age of 
25 years at risk for HD, familial cardiomyopathy or HBOC, the usefulness of pre-test counselling was seen in 
providing personalised information in a manner that could be easily understood. Across all three groups of 
conditions, individuals did not view the pre-test counselling as useful in facilitating the decision-making process. 
Some individuals took issue with the lack of information tailored to their specific situation and felt that the length 
of time between appointments could have been shortened. However, none of the participants believed that the 
age limit of testing should be lowered to under the age of 18 years for HBOC and HD (McLeod, et al. 2014). 
There is an overwhelming amount of research that has focused on the after-effects of both predictive and 
diagnostic genetic testing for HBOC but there has been little investigation surrounding the actual PT process 




influenced their decision to undergo PT for HBOC, we are better able to understand their evaluation of the actual 
PT procedure. Perspectives refer to their overall attitude towards the process or the manner in which they regard 
the PT process, whereas experiences refer to these individuals’ direct observation of the events that have 
occurred during the PT process (Claes, et al. 2005). 
To the best of our knowledge, there are no studies that have been conducted in a South African context, looking 
at the PT process, nor the factors affecting decision making, for HBOC. South African research efforts have largely 
focused on healthcare disparities and breast cancer survival (McKenzie, et al. 2016). Rayne, et al. (2017) recently 
explored the psychosocial stress affecting women already diagnosed with breast cancer in SA. The study 
concluded that increased fears at diagnosis were associated with the treatment of breast cancer and its adverse 
effects, as well as fears of dying. Affordability of cancer treatment was found to be the only significant socio-
economic factor to be associated with increased concern (Rayne, et al. 2017). Fear is an important factor that 
has been found to contribute to delayed treatment amongst individuals diagnosed with cancer (Otieno, et al. 
2010; Rayne, et al. 2017).  
Hallowell, et al. (2005) explored the factors influencing PT decisions in at-risk men in the United Kingdom. The 
study concluded that all the men in the study felt obliged to undergo predictive genetic testing for the benefit of 
their family members, their children in particular (Hallowell, et al. 2005). Research efforts have yet to focus on 
the characteristics of individuals, both men and women, and the psychosocial factors that affect their decision 
to undergo PT for HBOC (Sweeny, et al. 2014). The present study will aim to address this in a local context by 
focusing on South African individuals residing in the Western Cape Province. These individuals would have 
undergone PT for HBOC as a result of an already identified mutation for HBOC in an affected family member. 
This study will focus on the perspectives and experiences of individuals that have undergone PT for HBOC with 
the aim of assisting genetic counsellors and other healthcare professionals working with this group of individuals 
to provide more focused PT counselling sessions tailored towards the unique needs of these individuals in an 








2.3 AIM AND OBJECTIVES 
2.3.1 AIM OF THIS STUDY  
The aim of this research project is to qualitatively explore the perspectives and experiences of individuals who 
have undergone PT for HBOC in the Western Cape, South Africa.  
2.3.2 OBJECTIVES OF THIS STUDY  
The aim of this study will be achieved through the following objectives: 
1. To explore the participants’ experiences of undergoing a predictive test for HBOC.  
2. To explore the participants’ perceptions about undergoing PT for HBOC.  
3. To explore the factors that influence the participants’ perceptions and experiences of undergoing PT 
for HBOC.  
4. To explore what factors influenced the participants’ decision to undergo PT for HBOC. 
5. To explore how each participant perceives the PT process could be improved.  
2.4 CHAPTER SUMMARY  
In this chapter, PT for HBOC was discussed in further detail and the rationale for this study was presented. The 
study aim and objectives were presented. The methods employed in this study are explained in detail in the 












CHAPTER 3: METHODS 
3.1 CHAPTER INTRODUCTION 
This chapter includes (1) an outline of the research design and a rationale for the use of qualitative 
methodologies, (2) details of the study population and sample, data collection and analysis and (3) ethical 
considerations.  
3.2 RESEARCH DESIGN 
3.2.1 QUALITATIVE RESEARCH   
This study has been designed to be an in-depth qualitative study of the perspectives and experiences of 
individuals undergoing PT for HBOC. Since the aim and objectives of the study were to explore individuals’ 
perspectives and experiences of the PT process with regard to HBOC, a qualitative research approach was found 
to be most appropriate. Qualitative methodologies allow for the researcher to understand a phenomenon in a 
setting that is context-specific, natural and experienced by the participants themselves, a phenomenon that 
otherwise may be poorly understood (Golafshani, 2003). It allows for the contextualisation and understanding 
of peoples’ experiences in a real-world context, placing emphasis on their actions, thoughts and reflections, and 
investigates questions pertaining to their psychological and social interactions (Henwood, 2014).  
In addition, as only a limited amount of knowledge is available on this topic in the context of SA, an exploration 
of this phenomenon is initially needed, which is only possible using qualitative questioning of the phenomenon 
in order to find the significance that individuals place on this process. Qualitative research allows for the 
possibility of guiding clinical practice and improving service delivery in order to make a difference in the lives of 
those who are faced with similar situations (Merriam, 2009; Redlinger-Grosse, et al. 2015). In order to 
understand the phenomenon under study, it is important that the researcher set aside any prejudgements and 
previous experience of the phenomenon (Al-Busaidi, 2008).  
Genetic counselling necessitates that psychosocial aspects are addressed by a counsellor that has sufficient 
experience in dealing with emotional issues. A significant proportion of genetic counselling training and clinical 
practice is associated with interacting with individuals regarding sensitive and complex topics related to genetic 
conditions, similar to the skills that are required to conduct interviews. In addition, the skills, that are gained 
during the preparation of cases for presentation to colleagues and during patient follow-up, correspond to the 




(MacFarlane, Veach & LeRoy, 2014). Genetic counselling research therefore encompasses many of the objectives 
of qualitative research (Redlinger-Grosse, et al. 2015).  
3.3 STUDY POPULATION AND STUDY SAMPLE  
3.3.1 STUDY SETTINGS   
Research study participants were recruited retrospectively from the breast cancer and/or clinical genetics clinics 
at GSH, TBH and private genetic counselling practices in Cape Town (PVT). Individuals that have undergone PT 
for HBOC are seen through these genetics services. GSH and TBH are state-funded tertiary academic hospitals in 
the Western Cape that serve patients referred by less-specialised primary or secondary healthcare services. Both 
hospitals serve patients from different geographic regions in the Western Cape. Private genetic counselling 
practices serve patients that have private medical insurance or those that are able to pay private rates. It was 
important to recruit participants from multiple genetics services in the Western Cape so that the findings from 
this study could be representative of the perspectives and experiences of individuals undergoing PT for HBOC in 
the Western Cape and not just a reflection on the perspectives and experiences of individuals that had been 
through the process at one institution.  
Genetic counselling referrals for patients diagnosed with cancer are generally made by specialist physicians such 
as oncologists, gynaecologists or breast surgeons. Patients that are found to carry a BRCA1 or BRCA2 mutation 
are encouraged to notify their relatives about their risk of having inherited the same mutation and the availability 
of PT. Potential study participants were identified following a search of the various clinical databases and patient 
files. Participants that fit the study inclusion criteria (described in 3.3.2) were contacted if they had been seen by 
a healthcare professional and if they had completed the PT process for HBOC.  
3.3.2 STUDY POPULATION   
Participants, both male and female, were included to participate based on the following criteria: they needed to 
have undergone PT for HBOC and they needed to be older than the age of 18 years at the time of recruitment. 
These participants had positive family history of HBOC. All study participants that underwent PT for HBOC would 
have been at 50% for having inherited the familial risk-conferring variant prior to being tested. In addition, 
participants needed to have completed the PT process and received their results at least a month prior to the 
interview. Owing to the sensitive nature of the results, it was decided that this would be an appropriate time to 
allow participants to process their results and deal with the initial impact of what their results mean for them 
and their families. Participants were excluded from this study if they were cognitively impaired due to health 




that these individuals could be vulnerable to coercion or in the case of severe cognitive impairment, may lack 
the capacity to provide truly informed consent (Berg, 1996).   
In order to reduce the chance of introducing potential bias that accompanies the decision to only interview 
English speaking participants, it was important to provide the option of a suitably appointed translator and 
translated supplementary documentation for participants who did not feel comfortable communicating in 
English. Interviews were offered in English, Afrikaans or isiXhosa, the three main languages spoken in the 
Western Cape.  
3.3.3 SAMPLING METHOD  
The sampling method used in this research study was purposive sampling. Purposive sampling is a non-
probability sampling technique that may be subjective in nature but can be useful when the purpose of the 
research is not aimed at making generalisations that pertain to an entire population. Purposive sampling may be 
advantageous in smaller scale research and in instances where there are limited resources and time (Etikan, et 
al. 2016), such was the case in this research study. The participants in this study were selected based on the aim 
and objectives of this study as well as the knowledge and experience of undergoing PT for HBOC that each 
participant possessed. It was expected that each participant would be able to provide information that was both 
unique and valuable. The purposive sampling strategy used in this study was homogeneous sampling as the group 
of participants selected had some similar and defining characteristics (Bernard, 2017; Savin-Baden & Howell 
Major, 2013).  
Purposive sampling is most often associated with qualitative research as it allows for the identification of the 
most informative cases, with particular characteristics, that aid in achieving a depth of understanding about a 
particular phenomenon (Etikan, et al. 2016). With purposive sampling, the sample size is dependent on the point 
at which data saturation is reached (Wu Suen, Huang & Lee, 2014). This is the point at which novel themes and 
explanations no longer emerge from the data (Francis, et al. 2010; Marshall, 1996). Regardless of the technique 
employed, validity and efficiency are paramount (Morse & Niehaus, 2009).  
The original genetic counsellor, who performed the PT for each individual, was contacted telephonically or via 
email and was asked to contact potential interview participants informing them about the research project, its 
aims and objectives. This was ethically important as it protected the anonymity of these individuals, particularly 
in cases where they were not interested in participating, as well as their autonomy, as it may have been easier 
for them to make an autonomous decision about participating when asked by someone who they were familiar 




consent for the researcher to contact them. Individuals willing to participate were contacted by the researcher, 
telephonically or via email, the research aims were discussed further, and an interview date and time was set up 
at the participants’ earliest convenience. 
3.3.4 SAMPLE SIZE  
Sixteen participants were recruited to participate. The emphasis of qualitative methodologies is placed on the 
participants’ lived experiences and does not aim to enumerate. A large sample size and statistical 
representativeness is not regarded as an important requirement in qualitative research, and in some cases, may 
be impractical. The sample size is dependent on the purpose of the study as well as the availability of resources 
and the time constraints (Patton 2002). Qualitative research methods aim to collect information-dense data. 
Conversely, quantitative methods are deductive in nature and aim to obtain a breadth of understanding (Etikan, 
et al. 2016; Patton, 2002). During the interview process one interview was excluded from this study as it was 
found that this participant had been diagnosed with breast cancer a number of years prior to her testing, 
meaning that she had in-fact undergone diagnostic genetic testing and not PT. The remaining 15 interviews were 
analysed further during data analysis.  
I aimed to recruit 10-20 participants overall, from both the public and private sectors. As the aim of this study 
was not to identify differences between the public and private sectors but rather to obtain a comprehensive 
understanding of the perspectives and experiences of individuals in the Western Cape undergoing PT for HBOC, 
equal representation of the two sectors was not necessary. This predicted sample size was subject to change as 
the number of required participants became apparent as the interview process progressed and until data 
saturation was reached. Data saturation was reached after the 14th interview, not including the excluded 
interview. This was the point at which the interviews no longer provided new information on the phenomenon 
under investigation. A 15th interview was conducted and data analysis was able to confirm that data saturation 
had in-fact been reached. Qualitative analysis of research content during the data collection period allows the 
researcher to better navigate between the development of concepts and the collection of data. This is helpful in 
directing subsequent data collection so that it may be more useful in addressing the intended research question 
(Miles & Huberman, 1994; Zhang & Wildemuth, 2016). 
3.4 DATA COLLECTION   
Data was collected through the use of short socio-demographic questionnaires as well as face-to-face or 
telephonic interviews. Prior to the interview, consenting participants were given a socio-demographic 




demographic information that could be used as data for analysis. Interviews were conducted by the researcher 
using a semi-structured interview guide (appendix B). The questions in the interview guide were created based 
on information obtained from published literature pertaining to the subject of breast cancer. The interview guide 
included open-ended questions that were focused on the PT process for HBOC in the Western Cape.  
A semi-structured interview is characteristically based on flexible parameters that provide open-ended questions 
that are able to explore participant experiences and perceptions (Turner III, 2010). The advantage of the loose 
structure of open-ended interview questions is that they enable the interviewer to explore new areas that have 
not yet been explored by the researcher and enrich their data, as well as enabling them to build rapport with the 
participants (Al-Busaidi, 2008). 
The interview guide was reviewed by the study supervisors to ensure rigour of the study. Two test interviews 
were carried out in order to determine whether there were any limitations or weaknesses with the interview 
design and necessary changes to the questions were made prior to the implementation of the study. Open-ended 
questions were used to allow participants to fully express their perspectives and experiences. These questions 
were carefully worded to remove bias and ensure neutrality (Turner III, 2010). Follow-up probing questions were 
used as a means of eliciting additional responses or to provide context.  
These interview questions aimed to explore how the participants experienced and perceived the PT process. 
Based on the fact that interviews are aimed at exploring more sensitive issues, they were conducted in a quiet 
and private setting in an attempt to minimise distractions and to further encourage full disclosure of information. 
All of the interviews were conducted by the researcher and audio-recorded. Field notes were used by the 
researcher during the interview process in order to assist in taking note of both physical and verbal behaviours 
of the participant, as well as any features of the setting that may be useful during the data analysis (Mulhall, 
2003). By observing how people behave and physically interact in a particular setting and taking note of the 
emotions that are felt and expressed, the researcher is able to gain a better understanding of the social situation 
under study (Wolfinger, 2002). 
When arranging an appropriate time and place for the interviews, prospective participants who were willing to 
participate but were unable to travel to a suitable location for a face-to-face interview, or their working hours 
made it impossible for them to be available for a face-to-face interview, were given the option of having a 
telephonic interview. All participants were also given the option of having the interview conducted in a language 
other than English.  




3.5.1 APPROACH TO QUALITATIVE DATA ANALYSIS   
The framework approach was chosen for this research study. This approach allows for in-depth exploration of 
the data set and facilitates effective and transparent interpretation of the research findings. The systematic 
manner in which this analytical method is conducted is well suited for beginner qualitative researchers as it 
ensures academic rigour (Smith & Firth, 2011). This approach to qualitative data analysis was developed by social 
policy researchers during the 1980’s and has been increasingly used as a means of performing qualitative data 
analysis for healthcare related research. The framework method is part of a broad conglomerate of data analysis 
methods that are often referred to as thematic analysis (Smith & Firth, 2011). This approach is an analytical 
method that is guided by the original observations of the research participants and is open to change and 
amendment throughout the analysis process. Data analysis is conducted systematically through an 
interconnected four stage process, while allowing the researcher to re-visit and rework ideas afforded by the 
rigorous and transparent management of data (Smith & Firth, 2011). The researcher is able to move back and 
forth throughout the data to allow for the constant refinement of themes and subsequent development of a 
conceptual framework matrix (Spencer, Richie & O’Connor, 2003).  
Initially, the data analysis procedure requires that the researcher become immersed in the data that has been 
generated in an attempt to start sorting the raw data and determining themes that will then be applied to the 
data (Gale, et al. 2013). The interview recordings, field notes and interview transcripts were reviewed and read 
multiple times. This process was helpful in allowing the researcher to become familiar with the interviews and 
the data generated during the interviews. This first step is known as familiarisation and is important for 
subsequent data analysis (Spencer, Richie & O’Connor, 2003). Next, the data obtained from the first five 
interview transcripts was then carefully read and portions of the interviews that were relevant to the study were 
assigned codes which described the interpretation and the importance of the passage. Coding allowed for the 
data to be classified so that it could be compared systematically with other parts of the data set in order to 
identify recurrent themes and emerging ideas that were raised by the research participants throughout the 
interviews. These codes were then sorted and grouped into categories in order to construct a detailed index 
based on the issues that were raised in the interviews. These included issues that were introduced via the 
interview guide and new issues that were raised by the participants themselves based on the recurrence of 
specific experiences or perspectives. During this second step of data analysis a working thematic framework is 
identified and constructed (Spencer, Richie & O’Connor, 2003).  
The working thematic framework that was constructed in the previous step was then applied to the remainder 
of the data set. The complete data set was systematically coded according to the predetermined categories in 




categories to be summarised, linked to one another and grouped into specific themes (Gale, et al. 2013). The 
categorised data was then reorganised according to the appropriate theme which the information referred to. 
This allowed for the researcher to develop a holistic view of the data from each interview that pertained to each 
issue or theme that arose throughout the interview process. In this way, charting, which is the final step of the 
process, allows for the identification of themes and sub-themes in the data so that the findings may be addressed 
in context of the aims and objectives of the study and the emergent themes (Spencer, Richie & O’Connor, 2003). 
3.5.2 DATA ANALYSIS PROCEDURE 
The audio-recorded interviews were transcribed verbatim by the researcher to be used in subsequent data 
analysis. Each participant was assigned an alpha-numeric code in order to ensure privacy and confidentiality and 
any information that may have contributed to the identification of the participants was removed during the 
transcription. Field notes were taken during and after the interviews. A personal reflection was also noted by the 
researcher after each interview. All recordings, notes and supplementary documentation associated with the 
research was kept on a password-protected computer and backed-up to private cloud storage or kept under lock 
and key.   
The transcribed interviews were rigorously examined to identify themes according to the framework approach, 
in close discussion with the project supervisors. Thematic analysis is a non-linear, theoretically flexible method 
for analysing qualitative data that allows for the coding of data and describes the data set in detail (Braun & 
Clarke, 2006; Vaismoradi, et al. 2013). As described in the previous chapter, analysis and categorisation of data 
occurred simultaneously with data collection. This process was important to inform future interviews to explore 
issues that were raised in previous interviews. By listening to interview recordings and the ongoing reading of 
interview transcripts, early thoughts and ideas could be generated. Being able to engage with data is an 
important starting point in gaining familiarity, insight and understanding of the data generated and becomes the 
foundation for the data analysis (Mauthner & Doucet, 2003).  
The data obtained from the research project was coded and managed using the NVivo11 (QSR International) 
software program. This software was chosen as it facilitates qualitative research methods and it has been 
designed to facilitate the organisation and manipulation of data, enables the researcher to perform more 
complex searches, to visually explore the thematic framework and themes that have been generated and the 
security of the data is maintained, all in a time efficient manner (Al-Busaidi, 2008).  
The themes and sub-themes were developed according to the steps outlined in 3.2.2 and were developed in 




participants. Table 2 below is the framework matrix used to analyse the data. The framework matrix provides a 
visual representation of the initial categories and the codes assigned to each category that were developed 
during step two. The refined categories were then derived from the initial categories and in some cases, were 
derived from more than one of the initial categories. The final themes were then derived from the refined 
categories. The themes and sub-themes were discussed and reviewed by the researcher and study supervisors. 
Excerpts of the interviews were selected based on their representativeness of the ideas raised from the interview 
guide as well as emerging ideas for the presentation as results of this study.  
Table 2: Framework matrix detailing the development of the final themes 
Initial Categories Codes Refined Categories Final themes  
Family history of cancer  
 Impact of family 
history 
 Personal scares 
 Family support and 
communication  
 Awareness of risks 
Family history of cancer 
and factors influencing 
the decision to undergo 
testing 
















What now? Perceptions 





Support and its role in 
the predictive testing 
process 
Factors influencing 
decision to do testing 
 Family and children  
 Fear of cancer  
 Being supported  
 Personal experiences  
Influence of knowledge  
 Feeling empowered  
 Wanting to know  
 Attitude towards 
results  
 Residual risk  
 Family dynamics  
Post-test distress and 




 Number of sessions  
 Follow up and 
support  
 Provision of 
information  
 Other cancers  
 Timelines  
Being prepared, being 











Support and not being 
free of cancer risk   
Religion and personal 
beliefs  
 Religion  
 Feeling guilty  
 Effect on work and 
personal life  
 Attitude about being 
tested  
 Culture  
Surveillance and taking 
care of yourself  





 Advantages and 
disadvantages of 
knowing results 
 Lifestyle changes  
 Seeking support  
 Prophylactic 
intervention  
3.6 VALIDITY AND RELIABILITY  
Qualitative research is centred around non-numerical information and the manner in which this information is 
interpreted and made sense of. This interpretation relies on human emotions and perspectives of both the 
researcher and the participants, and is therefore subjective (Leung, 2015). The validity of qualitative research 
refers to the manner in which an account is interpreted by the researcher and whether it is an accurate 
representation of the phenomenon to which it relates. It addresses whether the research process and data are 
appropriate for answering the aim and objectives of the study. The choice of methodology needs to enable the 
detection of credible findings in an appropriate context in order for it to be valid. The interpretations and 
inferences made by the researcher needs to be rational in the context of previous research findings as well as 
being supported by the research (Waterman, 2013).  
The validity of a deduction is achieved when the interpretation is not made subjectively, but rather, the 
researcher has analysed the data and considered various possible cases so that a valid interpretation can be 
made (Silverman, 2015). Strategies for enhancing the credibility of qualitative research can be employed to 
produce more valid findings. These include reflexivity and reflections on the perspectives of the researcher, 
repeated reanalysis of the data to assess emerging ideas and remaining true to the accounts of the participants, 
and actively exploring deviant cases (Noble & Smith, 2015). To ensure validity, the researcher and study 
supervisors worked in collaboration to critically evaluate the data. Three of the interview transcripts were 
examined by independent supervisors and each generated their own codes. These codes were then reviewed 
with the researcher in order to challenge the researcher’s ideas and to ensure validity. These differences in 
interpretation were discussed until there was 100% agreement between the coders and the framework matrix 
was modified prior to it being applied to the remainder of the dataset.  
During the data analysis process, it was important that the researcher be reflexive and use reflective techniques 
in order to ensure that her own values and biases did not impinge on the manner in which the data was analysed. 
As a practicing genetic counselling student intern doing research on a condition that is seen in clinic, it was 
important for the researcher to be reflexive throughout this study. One of the important elements of reflexivity 




(Mauthner & Doucet, 2003). During the interview process, it was important for the researcher to set aside any 
personal beliefs and training experience in order to ensure that they did not affect the manner in which the 
interviews were conducted and the data was analysed. Additionally, it was important to be aware of the impact 
that the study findings could have on the researcher’s ability to conduct PT pre-test counselling sessions in clinic 
and to reflect on them after the sessions. Although the researcher was making a conscious effort to consider the 
impact of being a practising genetic counsellor and researcher at the same, it is acknowledged that some would 
still remain. 
Reliability refers to the consistency within the analytical procedures that have been employed and the future 
replicability of the research. These include taking account of any biases, personal bias and bias in the research 
methodology, that could have influenced the research findings. Reliability is achieved through a transparent and 
clear description of the research procedure, including the data analysis and reporting of findings. The framework 
approach to qualitative research is well-suited to achieving reliability. It is important that pauses, body language 
and subtle nuances are noted when audio-recorded interviews are transcribed in order to strengthen the 
reliability of the interpretation. Incorporating fieldnotes and observations into written transcripts and 
transcribing verbatim, including interviewer questions, will further strengthen the reliability of the study 
(Silverman, 2015). Discussion of emerging themes with the research team in an interactive process where 
inferences can be challenged to reach a consensus interpretation. This is important for achieving consistency 
within the analytical process (Noble & Smith, 2015). These strategies were applied to this study to ensure that 
the outcomes were consistent and reliable.  
3.7 ETHICAL CONSIDERATIONS 
According to the Declaration of Helsinki developed by the World Medical Association, some of the essential 
ethical principles for medical research involving human participants include respect for the individual, the right 
to make an informed choice as to whether or not to participate in the research, as well as the individual’s right 
to autonomy. These principles are paramount not only upon the commencement of the study but throughout 
the duration of the research (World Medical Association, 2011). It is important to remain mindful that the well-
being of the participant must always be prioritised over the interest of science and society. Ethical considerations 
should always take priority over laws and regulations.  
3.7.1 ETHICAL APPROVAL  
Ethical approval was granted by the University of Cape Town Faculty of Health Sciences Human Research Ethics 





Research participants were informed both in writing and via verbal communication that they would be enrolled 
in a research study in which the main objective was to assess how adults in the Western Cape, who have 
undergone PT for HBOC, perceive and experience the PT process. Each participant was notified that participation 
in the research was voluntary and that they were able to withdraw from the study at any given time without this 
affecting their current or future medical care. Participants were made aware that all interviews would be 
conducted in a private setting and that the duration of each interview would be approximately an hour. They 
were also notified that the interviews would be conducted in English and would be audio-recorded. Each 
participant was notified that should they require a translator, an appropriately suited translator would be made 
available to them at the time of the interview.  
All potential participants were provided with an information sheet (appendix C) outlining the details and purpose 
of the research and were required to consent (appendix D) to their involvement in the research in writing by 
signing consent forms. Each participant received a copy of the information sheet and the signed consent form. 
All participants chose to have the interview conducted in English and all supporting documentation did not need 
to be translated into another language.  
Informed consent is integral to medical research and is essential to ensuring the autonomy of the participant. 
Participant authorisation is granted based on the fact that they have a clear understanding of what the research 
activity entails and that they are not persuaded by others. Information pertaining to the research needs to be 
disclosed in a manner that can be comprehended by the prospective research participant so as to facilitate 
informed and autonomous decision-making. In some cases, it may necessitate the translation or further 
explanation of the consent form where necessary (Grady, 2015).  
3.7.3 PRIVACY AND CONFIDENTIALITY 
Ensuring the privacy and confidentiality of research study participants is imperative in research ethics. Every 
effort should be made to protect the privacy of study participants and keep their personal information 
confidential. In order to minimise the violation of participant privacy and confidentiality, only the data that is 
pertinent to this research topic was reported (Morse & Coulehan, 2015).  
All completed documentation, including consent forms and socio-demographic questionnaires, as well as audio 
recordings of the interviews were stored on a password-protected computer or under lock and key, to which 
only the researcher had access. All participants were assigned a de-identifying alpha-numeric code which would 




obtained during the research process would only be made available to the researcher, supervisors and examiners 
directly involved in the study. 
Following completion of the recruitment and interview process, all hard copies of documentation were 
converted to electronic copies, anonymised and stored on a password-protected computer. All documents and 
recordings will be retained by the minor-dissertation supervisor until such time that the data obtained from this 
study is published in peer reviewed journals.  
3.7.4 RISKS AND BENEFITS TO PARTICIPANTS 
Prior to obtaining consent, participants were advised that the information obtained would be for the sole 
purpose of conducting research. Some of the interview questions were of a particularly sensitive nature and may 
have evoked an emotional response that they may not have felt comfortable exploring. This was a potential risk 
to participants in this study. Cultural competency and the use of empathy were used to minimise these risks. 
Participants were also allowed to terminate the interview and withdraw from the study at any time, as well as 
seek counselling from a qualified genetic counsellor if deemed necessary. Participants were informed that if they 
chose to no longer participate in the study, for any reason, their decision would not in any way affect the standard 
of healthcare that they receive from the respective institutions. 
Providing participants with an opportunity to share their stories and with a platform to more effectively make 
sense of their condition and their lives, may be a benefit of participating in this study. Storytelling has long been 
used as powerful instrument of communication. Storytelling has been shown to have therapeutic benefits for 
patients living with cancer and enabling them to cope with their diagnosis (Chelf, et al. 2000).  Storytelling has 
also allowed for groups of individuals, with similar conditions or in similar situations, to be heard (Koch, 1998). 
The information that was obtained during the interview process will aid in improving our understanding of 
patient perceptions and experiences of the PT procedure for HBOC. This information will be beneficial for health 
care practitioners, including genetic counsellors, to understand and assess the efficacy of the PT procedure as 
well as the interventions that are employed to prepare patients for receiving their test results. 
3.8 CHAPTER SUMMARY   
The study methodology was outlined in this chapter. Qualitative research methods were used for this study 
and the rationale was explained. The study population and recruitment have been described in detail. The 
methodology has been described in full and the ethical considerations have been discussed. The subsequent 




CHAPTER 4: RESULTS AND DISCUSSION  
4.1 CHAPTER INTRODUCTION  
This chapter will (1) include a summary of the socio-demographic characteristics of the study participants, (2) 
describe the themes and sub-themes that have been identified during data analysis, and (3) present and 
discuss these themes in the context of the current research, providing interview excerpts in support of the 
findings. Where appropriate, existing research is presented to further the interpretation of the themes.  
4.2 SOCIO-DEMOGRAPHIC CHARACTERISTICS OF STUDY PARTICIPANTS    
The intention of this study was to recruit participants that had undergone PT for HBOC in the Western Cape, 
South Africa. Twenty-two participants were originally recruited for this study. All study participants were 
originally from SA. The age of participants ranged from 19-79 years and most were in a stable relationship. The 
majority of the participants were female (12/15). Five of the participants did not have children, while the number 
of children in the remaining participant’s family ranged from one to four. Nine of the participants went through 
the PT process at GSH, two at TBH and the remainder through a private genetic counsellor. Fourteen of the 
fifteen participants had received their results between 1-2.5 years prior to being interviewed and one participant 
had their result for 2 months prior to being interviewed. Participants 11 and 16 were the only two participants 
whose first language was Afrikaans. The remainder of the participants’ first language was English. A summary of 
the sociodemographic data of the participants is presented in table 3. 
Table 3: Summary of socio-demographic information of study participants 
Code Age Gender 
Stable 
Relationship 




P1 37 F N 0 Y Tertiary Negative GSH 
P2 39 F Y 4 Y Tertiary Positive GSH 
P3 33 F Y 2 Y Tertiary Negative GSH 
P4 40 F Y 3 Y Secondary Negative GSH 
P5 33 M Y 3 Y Secondary Negative GSH 
P7 34 F Y 2 Y Tertiary Positive PVT 
P8 79 F N 4 N Primary Positive GSH 
P9 36 F Y 2 Y Secondary Negative GSH 
P10 58 F N 0 Y Tertiary Negative PVT 




P12 19 F N 0 Y Secondary Negative GSH 
P13 30 M Y 0 Y Tertiary Negative PVT 
P14 51 M Y 0 Y Secondary Positive GSH 
P15 51 F Y 3 Y Tertiary Positive PVT 
P16 35 F N 1 N Secondary Positive TBH 
F: Female, M: Male, Y: Yes, N: No 
Nine participants were from three different families (P1, P2 and P3; P4, P5 and P9; P8, P12 and P14). The 
relationships between these individuals are depicted in the pedigrees below. The cancer affected status and 
carrier status of family members have been deliberately omitted so as not to allow for the identification of 
families.  
 
Figure 1: Pedigree showing the relationship between P1, P2 and P3. Circles represent females, squares represent 





Figure 2: Pedigree showing the relationship between P4, P5 and P9. Circles represent females, squares represent 
males and diamonds represent ‘n’ number of individuals of unknown gender.  
 
 
Figure 3: Pedigree showing the relationship between P8, P14 and P12. Circles represent females, squares 




4.3 IDENTIFIED THEMES  
The following themes and sub-themes were identified as described in chapter 3 and are summarised in table 4 
below. Each of the themes and sub-themes will be discussed in the sections to follow.  
Table 4: Themes and sub-themes identified 
Theme Sub-themes 
To test or not to test  
- Sense of duty  
- Reconciled to being positive  
Head knowledge versus emotional knowledge  
- One hour isn’t enough 
- The bigger picture  
What now? Perceptions of the process 
- Additional support  
- It should have been me  
Consequence of knowing  
- I’m not cancer-risk free  
- It’s the disfigurement 
- Empowered by knowledge  
Support and its role in the predictive testing process  
4.4 THEME 1 – TO TEST OR NOT TO TEST 
Participants are often introduced to the concept of PT for HBOC once a molecular genetic diagnosis has been 
made in an affected family member. In cases where there is a significant family history of cancer, individuals may 
be aware that they are at an increased risk from a young age. The findings presented in this theme illustrate the 
role that cancer burden plays in an individual’s perception of developing cancer and the sense of duty to take 
action, either to prevent a cancer diagnosis or to allow for the detection of cancer as early as possible. The 
findings will also highlight the beliefs that people develop based on their family history of cancer. Participants in 
this study felt that their decision to pursue PT was motivated out of a sense of duty to their children or families 
or as a result of their family history of cancer and the associated cancer-related stress.  
4.4.1 SENSE OF DUTY  
Genetic testing for cancer susceptibility in healthy at-risk individuals affords them the opportunity to be informed 
about their mutation status and they are able to potentially benefit from the preventative surveillance and 
prophylactic options that are available to mutation carriers (Menko, et al. 2018). PT has provided individuals with 




important consequences for individuals who test negative for the familial pathogenic variant. A negative test 
suggests that the individual is not at an increased risk for developing cancer and that preventative surveillance 
and preventative measures are not necessary. It also implies that any present or future children of these 
individuals have no increased cancer risk (Menko, et al. 2018).  
While exploring the factors that influenced the participants’ decision to undergo PT and what worried them most 
about not knowing their mutation status, many of the participants explained that they felt a sense of duty to 
their children or their families to know whether they carried the disease-causing mutation or not. They said that 
they had a responsibility to the current and future generations to determine their risks. This is illustrated in the 
following quotes: 
“The other reason for me is that my kids are small, I can’t be dumb. I need to take care of myself in order 
to take care of them. If I have cancer like in five years’ time it’s okay they’re older, you know what I mean, 
it’ll be easier, I’m not saying its … Ja1 … but it’ll be easier then. If I can do something to help myself now I 
must do it.” (P2) 
“So, you’ve got all this questions, so, for me it was more about myself and my family and my children 
because my boys are so young and I was weak. How could I leave them behind so young and I still have 
to teach them so much?” (P9) 
 “For my girls. So, for, as I said, for what I’ve passed on and for me being a young mom, it’s always been 
in the back of my mind knowing that my mom’s strong family history and then I’m a girl, not to say that 
it’s only girls” (P7) 
The above quotes also illustrate how the female participants with young children felt that it was important to 
know their risks and take action where necessary because their children still needed to be taken care of. The 
right to know one’s genetic information is often relinquished in cases where the individuals feel that they have 
a duty to their families to determine the extent of their risk and the risk to other members of their family 
(Biesecker, et al. 2000; Hallowell, 1999). While the knowledge obtained as a result of PT is perceived to be 
empowering, this freedom to choose becomes constrained as individuals, women in particular, may feel that 
their increased risk means that they have a responsibility to engage in risk-reducing behaviours. Additionally, 
there is a presumed responsibility to protect the health of future generations (d'Agincourt-Canning, 2006; Foster, 
et al. 2002; Hallowell, 1999).  
                                                          




Most of the female participants who had children felt that, as mothers, it was their duty to determine and 
manage their risks for the benefit of their children, and particularly in cases where they were aware of the fact 
that if they were to test positive their children would also be at risk of inheriting the mutation. These participants 
expressed that they feared the idea of their children having to grow up without a mother or with a mother who 
was suffering from cancer. Society positions women as being responsible for taking care of others, particularly 
their children (Hallowell, 1999; Hallowell, et al. 2006). These women ascribed to these notions and felt that they 
had a responsibility to determine their risks and engage in medical interventions in order to alter their risk status 
so that they could fulfil their duty to care for others. Meijers-Heijboer, et al. (2000) demonstrated that being a 
parent was a strong predictor for the uptake of PT in both men and women. This is seen in the following quote 
by participant 7: 
“So, after having my two girls my, it was very important for me to go and get tested, it had always been 
something that I had wanted to do” (P7) 
The notion that individuals are at increased risk and that these risks can be managed suggests that individuals 
have a responsibility to try and modify these risks where possible (Foster, et al. 2002; Hallowell, 1999; Scott, et 
al. 2005). This perceived obligation to know one’s risk for the benefit of others threatens the concept of 
autonomous or independent decision-making suggesting that the needs and well-being of family members are 
seen as an integral part of the individual (d'Agincourt-Canning, 2006; Hallowell, 1999; Kenen, 1994).  
Some of the participants who did not have children expressed similar feelings. They felt it was important to 
establish their risk status so that it would allow for informed family planning. By simply knowing that other family 
members carried the mutation, there was a perceived responsibility to determine their own risk and the risk of 
their future children. Men, in particular, most often define their decision to undergo PT as a moral duty to their 
family, especially their children. The choice to pursue PT is motivated by the desire to avoid causing children 
future harm, something that can be achieved by knowing one’s mutation status (Hallowell, et al. 2006). One 
participant described that knowing whether his future offspring would be at risk was an important factor 
influencing his decision:  
“like I wouldn’t want to have kids and then be like oh well maybe they do maybe they don’t” (P13) 
In cases where an individual’s sibling or close family member has been diagnosed with cancer or has been found 
to carry the mutation, there may be a perceived responsibility to also be tested. Some study participants 
explained that they had chosen to pursue PT in solidarity with those family members who had either tested 




“What motivated me, I think it was more and this may sound silly but, but more to show solidarity with 
my sister and my sister-in-law. Who am I to say no I don’t care, I can have the gene it’s got nothing to do 
with me, I thought yeah, I think it was more for them, I just realised.” (P10) 
“I think it was mostly for my sister. You know what, she was so strong. She was stronger than all of us.” 
(P4) 
Similarly, participant 14’s comment explains how the decision to pursue PT was based on providing moral 
support for a family member: 
“I decided to go with my niece and get tested as well but more as a support for her, not thinking about 
myself” (P14) 
Even for those individuals that expressed that having a positive test result would cause them distress and that 
they weren’t sure how they would cope with the diagnosis, they chose to pursue testing in solidarity with a family 
member that had been diagnosed with cancer or because all their other siblings were being tested and they felt 
that, regardless of the outcome, it was the right thing to do. A study by Biesecker, et al. (2000) found that 
individuals from cohesive families were more likely to pursue PT. These individuals presumably had a greater 
amount of support that could be a beneficial resource during stressful events (Biesecker, et al. 2000). This finding 
is supported by the presence of participants from three different families in this study and is illustrated in the 
following quote by participant 3 who was tested with her siblings:  
“The three of us went together for the counselling, so that was quite nice, you know, we would know that 
we are in it together.” (P3) 
Many participants who underwent PT alongside family members found comfort in the fact that they were not 
on their own and that they were able to share the experience and support one another.  
4.4.2 RECONCILED TO BEING POSITIVE  
Fears about developing cancer and being at an increased risk for developing cancer were amongst some of the 
most common factors influencing the participants’ decision to pursue PT. It has been seen that having a positive 
family history of cancer can result in increased cancer-related distress. Experiencing a parent, sibling or family 
member being diagnosed and living with breast or ovarian cancer, or both, can alter the way in which individuals 
perceive their risks for developing the same condition (Biesecker, et al. 2000; Hirschberg, Chan-Smutko & Pril, 




It was found that the long awareness of a family history of cancer and the integration of increased cancer 
awareness into routine family life can alter the way in which a family functions and how individuals within these 
families perceive their personal risk for developing cancer. This finding is in agreement with Hirschberg, Chan-
Smutko & Pril (2015) who identified that experiencing the loss of a relative to hereditary cancer, especially young 
children losing a parent, can have a significant effect on the development of psychological distress during the 
period of predictive genetic testing for cancer susceptibility. The following interview excerpts demonstrate how 
family history impacted the decision to test:   
“And so, it suddenly became like really real and frightening, you know. It was a big thing for us. Suddenly 
instead of having like our cousins get togethers at home playing 30 seconds, we were visiting people in 
hospital and just praying that they be okay.” (P2) 
“there’s a long line, so all the females on my mom’s side have suffered from breast cancer or ovarian. So, 
the family history was extremely strong and that’s why I went to go and see [the genetic counsellor].” 
(P7) 
The experience of cancer in a family can influence an individual’s perception of their own vulnerability to 
developing cancer or worrying about other relatives developing cancer (Foster, et al. 2002). While PT is useful in 
identifying individuals that are at an increased risk for developing cancer, there is great uncertainty surrounding 
the predictive value of the testing. The penetrance estimates for BRCA1 and BRCA2 mutations and the age at 
which the cancer develops are largely variable. One of the aims of pre-test counselling is to address these 
uncertainties and to present these risks in probabilistic terms. Prior knowledge of the familial mutation allows 
for more tailored risk communication, including gene-specific penetrance estimates and age-related risks (Evans, 
Skrzynia & Burke, 2001; Lalloo and Evans, 2012). However, many of the participants felt that developing cancer 
was more of a certainty rather than a probability. The probabilities communicated to the participants during the 
pre-test counselling did not appear to alter their perception of risk, which is likely influenced by an extensive 
family history of hereditary cancer.  
During his interview participant 13 explained how when he had been given a lifetime risk estimate of 30% chance 
for developing breast cancer he felt that the decision to not pursue testing would be too much of a gamble. He 
explained how his experiences of regularly finding out that another one of his relatives had been diagnosed with 
breast cancer or tested positive for the mutation had made the 30% risk feel like it was higher than it actually 




“When you look at it, it’s 30% and you think you can take a chance. I suppose anything under 10% you 
think okay well that’s unlikely but 30% on its own just feels like a certainty. As much as I understood that 
just because you have this you can still live and that it might never materialise, it I think for me it felt like 
at some point you’re going to get cancer.” (P13) 
This finding supports literature which suggests that it is more common for patients to overestimate rather than 
underestimate their risks relative to the genetic risk values communicated to them (Scott, et al. 2005). Previous 
studies have also identified that some individuals attending genetic counselling sessions perceive their risk 
estimates as being binary, suggesting that the given condition will either develop or not (Hallowell, 1999). The 
perception of risk is largely influenced by social and personal factors, including family history (Scott, et al. 2005). 
Similar observations were made in this study which suggested that in many cases the individual’s perceived risk 
was influenced by experiences of cancer in the family.  
Experiencing the death of close relatives diagnosed with cancer or having a family member diagnosed with 
cancer appeared to influence the perceptions of being ‘at-risk’. Participant 12, who underwent testing alongside 
a family member, explained how living with the thought of possibly having cancer was scary. By experiencing the 
death of her mother at a young age, she believed that she would be more likely to test positive.  
“I was expecting a positive result, so I was expecting to have the gene because of my mother passing 
away of cancer. So, I thought okay, I thought I was going to be the only one that would come out positive.” 
(P12). 
Other factors influencing the participants’ decision to undergo PT included preconceived ideas about the 
aetiology of cancer and the influence of personal health factors such as previous cancer scares, having other 
serious medical conditions and the effects of how living a stressful lifestyle could impact the development of 
cancer. Many participants explained that the cancer-related worry that they experienced while attending annual 
mammography and gynaecological screening is what influenced their decision to know whether they carried the 
mutation or not. Participant 1 explained that an initial breast-cancer scare at a young age is what prompted her 
decision to pursue testing:  
“I think because I had my initial scare when I was twenty, that just spurred me on.” (P1) 
“To test or not to test” illustrates the participants’ initial journey prior to undergoing PT. While each participant’s 
experience is distinct, the factors influencing the decision to pursue testing were largely centred around 




members and children. Theme 2 addresses the experiences of the predictive testing process and how it prepared 























4.5 THEME 2 – HEAD KNOWLEDGE VERSUS EMOTIONAL KNOWLEDGE 
The second theme identified was the participants’ experiences of the pre-test counselling. The participants, 
overall, expressed having a positive experience with the counselling process. The participants reflected on how 
they felt the pre-test counselling prepared them for receiving their results. The findings presented in this theme 
illustrate how the provision of tailored information during pre-test counselling may not always be sufficient to 
preparing individuals emotionally for receiving their result. The findings will also highlight the perceived 
distinction between what it means to be prepared as a result of being equipped with accurate information and 
what it means to be emotionally prepared for the impact of the test result. Some participants in this study felt 
that the one hour of pre-test counselling was not sufficient in preparing them emotionally to receive their result.  
4.5.1 ONE HOUR ISN’T  ENOUGH 
As discussed in theme 1, the diagnosis of breast or ovarian cancer in a family can create a significant amount of 
distress in individuals that are closely related to the affected individual. While the majority of participants only 
had a single, one hour long pre-test counselling session, a few participants did attend more than one session 
prior to receiving their results, in most cases because they were accompanying other family members who were 
going through the process at the same time. Most participants explained that they were happy with the pre-test 
counselling session and that they felt that the counselling had prepared them to receive their results, regardless 
of the outcome: 
“I was completely happy. And, you know, we had the opportunity at all points to ask questions. So, yes 
that obviously helps. It wasn’t a one-sided conversation, it was quite good.” (P3) 
“I was prepared for whatever was going to happen. Whether it was positive which I really thought I was 
going to be or negative, which I am, so I was very prepared for whatever was going to come.” (P12) 
However, there were some participants that felt that while the pre-test counselling helped them insofar as to 
have an opportunity to improve their knowledge by meeting with someone who could provide them with the 
necessary information, in terms of risk estimates and inheritance patterns, it was the support from their families 
and their personal experiences in dealing with a family history of cancer that helped prepare them for receiving 
their results. This was not specific to receiving a positive result and is depicted in the following statements: 
“I think because I was at the end of a, not the end, but after a number of other people I think their 




it was good to speak to her and get the specifics but I think a lot of the counselling aspect had been done 
by, through discussion with different family members beforehand.” (P13) 
“I think the most important part that prepared me for getting my results is my family. That was the most 
important part.” (P9) 
“If I had to go alone then I would be in a mental state because I wouldn’t know what to expect, what 
would they ask, what do I do, where do I go. So, I would say that the family support structure prepared 
me for the overall thing.” (P5)  
Having had the opportunity to talk about it as a family and understanding what the testing process entailed based 
on the experiences of other family members, as well as the support of family members whilst going through the 
PT process is what helped in preparing these participants to receive their results. In addition to these comments, 
one participant explained that the counselling session didn’t help prepare her for the possibility of obtaining a 
positive result:  
“I wouldn’t say that the time with her, I enjoyed speaking to her and listening to her and get some more 
information, understanding and knowledge but I wouldn’t say that really prepared me. I would say that, 
if I recall correctly, that was more clinical, this is what it’s about, the gene test. It was something that I 
had to work through in my own head.” (P10) 
“I really enjoyed the session and she is a kind person and yeah it was good for me to be there but I can’t 
say that that hour or half an hour whatever time it was, that that helped me to deal with the possibility 
of a positive, I can’t recall that.” (P10) 
The above quotes illustrate how participant 10 was grateful for the opportunity to consult with a specialist and 
improve her knowledge about HBOC, but she felt that the pre-test counselling was an interaction that involved 
the communication of clinical information. Dealing with the possibility of receiving a positive test result was 
something that she felt she had to work through in her own time and not during the pre-test counselling. The 
distress that individuals experience while going through predictive genetic testing and following result delivery 
has been previously studied by Hirschberg, Chan-Smutko & Phil (2015). They identified that distress is influenced 
by several factors including availability of support and coping styles. Personal experiences in dealing with a family 
history of cancer and the support of family members are described in this study as a means of preparing 




A study by Cox (2003) explored how individuals at risk for HD make the decision to request PT. The author 
describes how five of the 16 study participants that chose to pursue PT felt that the decision was something that 
they had evolved towards. Living with a long awareness of a family history of HD and having an affected parent 
in the preceding years resulted in participants experiencing increased levels of anxiety about learning that they 
were at risk for HD and possibly having inherited the mutation as well as the imminent onset of the condition. 
There is often a period of weighing up the usefulness of knowing one’s mutation status and deciding whether or 
not to know if they have inherited the disease-causing mutation, therefore suggesting that the decision to pursue 
testing is often made prior to starting the PT process (Cox, 2003).  
It is possible that these findings would also apply to participants undergoing PT for HBOC. Similarly, some 
participants in the present study felt that their decision to pursue testing was influenced by their family history 
of HBOC, experiencing the death of an affected relative or living with a relative diagnosed with breast or ovarian 
cancer. Their long awareness of the condition and their personal experiences is what influenced their willingness 
to know and be tested when PT was made available to them. Considering the fact that all study participants had 
undergone testing and received a result, they must have, at some stage, contemplated the benefits of knowing 
their mutation status. Interestingly, all of the participants that felt that the pre-test counselling was not sufficient 
in helping prepare them for receiving their results were also identified in the previous theme as choosing to 
pursue testing out of a sense of duty to their families or in solidarity with family members that had already been 
tested. This may mean that these individuals had not thoroughly explored the possibility of receiving a positive 
test result as their motives for doing the test were focused on supporting a relative. In addition, the one hour of 
pre-test counselling would not have been enough to prepare them for the possibility of receiving a positive test 
result. The role of pre-test counselling in the PT process will be discussed in further detail in the following sub-
theme.  
4.5.2 THE BIGGER PICTURE   
As introduced in the previous theme, there are numerous factors that were found to influence an individual’s 
decision to pursue PT for HBOC. These included a family history of cancer, cancer-related distress and a perceived 
sense of duty to family members and children. While some study participants felt that the pre-test counselling 
sufficiently prepared them to receive their results, there were other participants who didn’t feel the same way. 
For some participants, as demonstrated in the previous sub-theme, it was the support from their family members 
and their family history of breast and ovarian cancer that helped prepare them. Participant 10 said that the 




It is important to consider the bigger picture and where the pre-test counselling session fits into it, in the context 
of the individual and their unique story. It is also important to understand what factors prepare a patient for 
receiving their result. Having a better understanding of the factors motivating individuals to pursue testing, their 
personality traits and coping mechanisms used when facing the possibility of receiving a positive test result, the 
effectiveness of pre-test counselling may be enhanced (Biesecker, et al. 2000). A study by Lodder, et al. (2003) 
found that distress is more likely to occur in individuals at risk of being carriers if they have experienced the 
serious repercussions of cancer in their family.  Considering prophylactic intervention and anticipating that their 
problems will increase if they are identified as a carrier, were amongst some of the factors found to increase 
distress in these individuals. In some cases, individuals may decline testing because they feel that they are not 
emotionally prepared to deal with the consequences of receiving a positive test result (Lodder, et al. 2003).  
Pre-test counselling for individuals undergoing PT for HBOC is focused on collecting relevant medical and 
psychological information about the patient, providing the patient with information about HBOC and the testing 
process and exploring the impact that the testing could have on the individual and their lives going forward. In 
some cases, medical management options are discussed and patients are encouraged to get their affairs in order 
with regard to life insurance and medical insurance in an attempt to prevent future insurance discrimination 
(Lerman & Shields, 2004).  
While the pre-test counselling content is tailored for each individual, the genetic counsellor or clinician providing 
the service is not familiar with each individual’s unique life story nor do they administer personality assessment 
tools to obtain a better understanding of the individual’s personality or coping styles. These healthcare providers 
are reliant on the information that their patients are willing to share with them or that they are aware of 
themselves. Therefore, it is impossible to be aware of all the factors influencing an individual’s decision. Genetic 
counsellors from the various institutions sampled in this study describe a similar approach to pre-test counselling, 
covering the same content. This is illustrated in the following interview excerpt by participant 3:  
“I think the process was very good because we went in there first having to state what we know about it, 
what were our expectations, etc. What would we do if we were to test positive, what we would do if we 
were to test negative, why we doing this. So, we were very … so you either well informed or you are not. 
So, I think she helped guide us and make sure we were going in the right direction with what we are 
thinking about. It was good, it was really good, it was very informative. And it helped prepare you for 
either outcome, so, even if you were negative, it doesn’t mean you are, it doesn’t mean you will never get 





When asked about the provision of psychological support during the pre-test counselling period one genetic 
counsellor explained that unlike the South African PT protocol for HD, which necessitates that individuals 
undergoing PT consult with a clinical psychologist prior to receiving their results, there are no formal South 
African guidelines for individuals undergoing PT for HBOC. Therefore, the decision to refer patients for additional 
psychological support is at the discretion of the clinician or genetic counsellor providing the service. In some 
cases, patients may request a referral or personally seek out additional psychological support.  
Emotional distress is an important factor to consider in the PT process. Higher levels of emotional distress have 
previously been found to be associated with decreased satisfaction with information provided during pre-test 
counselling, as were familial dysfunction and greater perceived cancer risk (O’Neill, et al. 2017). The provision of 
information can be an effective way in which to manage uncertainty. Patients are able to increase their 
knowledge and understand their situation, which provides them with a greater sense of control and facilitates 
informed decision making (Dean, et al. 2017). In line with this, some participants in this study felt that the 
information provided during pre-test counselling helped them to cope with their situation: 
“It helped me, expanded my knowledge about everything and yeah they just helped me cope a bit more, 
I felt better.” (P12)  
However, there were participants that explained that should they have received a positive result they weren’t 
sure if they would have coped. This is illustrated by the following quotes by participant 13: 
“And then again, you know, positive [mutation-negative] it was fine, there was nothing to worry about. 
Whereas if it was negative [mutation-positive], maybe I would’ve regretted it, maybe I would’ve regretted 
it, you know, I don’t know, maybe I would have been unprepared, I don’t know how I would’ve responded 
in that situation.” (P13) 
“But again, my results came out as being okay. If I had found out that I did have this gene, I’m not sure I 
would’ve been, you know, I don’t know how I would have dealt with it. And I thought oh I would’ve done 
this I would’ve done that but I don’t know how emotionally prepared I would have been to receive a no.” 
(P13)  
Based on the various responses received from participants in this study, additional psychological support prior 
to result delivery may not benefit all patients undergoing PT for HBOC but it may be beneficial to some. It is 
important to take into account the fact that while the majority of participants felt that the pre-test counselling 
sufficiently prepared them to receive their results, many of these participants were found not to carry the 




found to be mutation carriers. It is important to therefore consider what each participant believes what it means 
to be prepared. For some, it was the factual information and improved understanding and for others it was 
knowing that they had the support of their family members.  
One of the study participants described this a difference between “head knowledge” and “emotional 
knowledge”. While the provision of information tailored towards the specific needs of the client may prepare 
participants for the possibility of receiving a positive result, it is difficult to determine beforehand if they are also 
emotionally prepared. The pre-test counselling may be sufficient in improving “head knowledge” but based on 
the findings of this study, in some cases, it may be lacking in improving “emotional knowledge”.  The capacity to 
improve this “emotional knowledge” is limited by the time constraints of the pre-test counselling session and 
the healthcare provider’s ability to identify aspects of an individual’s personality and their coping styles within 
this time frame.  
The second theme encompasses the participants’ experiences of the PT process, in particular the role of pre-test 
counselling in preparing individuals to receive their results. While most of the study participants felt that the pre-
test counselling sufficiently prepared them for receiving their result, there were some participants that felt that 
it was their personal experiences in dealing with their family history of cancer and support from their family 
members that prepared them for receiving their results. The tailoring of pre-test counselling content may not 
always be sufficient in preparing individuals emotionally for receiving their result. As discussed in this theme, it 
is important to consider the bigger picture and the unique factors influencing an individual’s decision to pursue 
testing. Following the pre-test counselling, the participants then chose to proceed with molecular genetic testing 
and then received their results once they were available. The participants’ post-test perceptions will be further 











4.6 THEME 3 – WHAT NOW? POST-TEST PERCEPTIONS  
Participants that received a positive result felt that they required additional support following result delivery, 
this included practical, emotional and social support. These findings also highlight the fact that receiving a 
negative result does not always minimise distress as some individuals felt guilty about not carrying the mutation. 
One participant described her experience of feeling isolated as a positive mutation-carrier.  
4.6.1 ADDITIONAL SUPPORT 
A significant sub-theme that arose, particularly amongst the positive mutation carriers, was the need for 
additional support following a positive diagnosis. This included both practical and emotional support. Concerns 
were raised about the fact that there is no holistic service geared towards supporting individuals who are 
mutation-positive. BRCA1 and BRCA2 mutation carriers often face difficulties when making decisions regarding 
the best manner in which to manage their breast cancer risk. They need to decide between screening or 
prophylactic intervention. This decision is often made without clear direction as to which option is best for them. 
(Brunstrom, Murray & McAllister, 2015). This is highlighted in the following quotes by participant 2: 
“This lady that I go to now, she does mammograms but it’s not a holistic service geared towards 
supporting you as a person who is BRCA positive. So, I feel that is lacking. Like afterwards I was a fish now 
out of water trying to be a professional in something that is not my profession. I now had to say … and 
then I had to convince my husband who is this, you know, who is now basically standing there saying 
okay what are you doing, how do you know what you’re doing is right? I don’t know but I’m doing the 
best that I can.” (P2) 
“So, that I feel is lacking and so now it’s up to me to make sure that I do things. So, I feel like, you know, 
if I’m missing something or if there’s something new or whatever, unless I go and dig, I’m not going to 
find it. Whereas if I go to a professional that provided a holistic service, I would feel more at ease, if that 
makes sense.” (P2)  
Similarly, other participants expressed that they wanted additional support from established support structures 
or individuals that had been through similar experiences. This is illustrated by participant 7:  
“But if I had someone to talk to and maybe someone who is like me, it could help and to say okay well, 
you know, you might feel this you might feel that, you might have to have that extra procedure or even 
if this person was just having one operation and be like well why do you feel so scared, it’s not actually 




human, kind of interaction and someone’s experience, you know because no one experience is the same 
but, and everyone’s lives are different, but if you can help in anyway and it’s you know, by talking to 
someone then I think that would be helpful.” (P7) 
Participant 2, in the above quote, describes how not only did she feel overwhelmed by the test results, but she 
felt that she would have benefitted from consulting with a medical professional who provided a holistic service 
geared towards the surveillance of individuals who are mutation positive or by having a formal support structure 
to help guide her in making sure that she was taking the necessary steps and precautions to manage her risk. 
Similarly, participant 7 felt that she would have benefitted from an experienced individual’s guidance and 
support. The need for additional support after a positive predictive test is also supported by the finding that 
there were some participants who sought out additional emotional support and psychotherapy after receiving 
their result.  
Genetic counselling has been shown to play an integral role in managing the levels of anxiety and distress 
amongst these individuals by empowering them to make informed and autonomous decisions about possible 
treatment, engaging in preventative behaviours and managing the perceptions of risk (Scott, et al. 2005). The 
uncertainties associated with being neither sick nor healthy can create new concerns for these individuals as 
they attempt to integrate their risks into their way of life. There is an increased awareness that they may develop 
cancer within a particular time frame without knowing if or when it will happen (Harmsen, et al. 2015; Scott, et 
al. 2005).  
A study by Harmsen, et al. (2015) analysed the effect of medical decision making on the quality of life of women 
with a BRCA1 or BRCA2 mutation. Females with a BRCA1 or BRCA2 mutation were shown to present with 
increased cancer-related distress and worry and an increased perception of risk within the first year following 
receiving their genetic testing results. Distress levels do tend to fluctuate around times of surveillance visits and 
abnormal screening results. Decreased levels of distress and cancer-related worry were observed following risk-
reducing interventions. Females that opted for prophylactic surgery displayed high levels of satisfaction with 
their decision (Harmsen, et al. 2015). These findings support the findings of the present study as participants 
who were found to be mutation carriers felt that they had higher cancer-related distress following a positive 
diagnosis and that around the time of surveillance visits they were highly distressed. Participants that underwent 





One of the most robust predictors of future psychological distress is the distress present at baseline. Individuals 
that have greater baseline distress are at an increased risk for future psychological distress (Hirschberg, Chan-
Smutko & Pril, 2015). This is illustrated in the following interview excerpt:  
 “It was that kind of trauma that just, it was just an ongoing thing and people always say to you 
sometimes forewarned is forearmed, they say that, but with that also don’t tell you is that when you 
have the kind of anxiety that I have, you have a tendency to want to know more and sometimes the 
more you know the worse for you because then your brain starts playing all the signs.” (P14) 
“When you’re lying down watching TV and all of a sudden something comes to mind, now I’ve been 
carrying that two heavy bags from where I live to the hospital and back. So now I’ve obviously pulled a 
muscle in my back or something, and now I’m lying watching TV and I’m like hey what’s that pain, and 
my God could this be the start of it. And then I’ll start Googling.” (P14) 
Participant 14 was the only male participant that was found to be mutation-positive. The above quote illustrates 
that knowledge of his mutation status resulted in increased levels of anxiety and cancer-related distress. This 
participant also explained that as a naturally anxious person, the positive result had a negative effect on his 
psychological well-being. This participant also felt that he is now constantly aware of changes to his body and 
that he may perceive normal pains as being possible signs of developing cancer.  
Hesse-Biber (2014) found that the perceived risk of developing cancer amongst female study participants was 
not based on the statistical risk values provided by a physician or genetic counsellor but rather reframed in the 
context of important factors including family history, personal experience of living with a relative that had been 
diagnosed with cancer or died from cancer and the availability of support and information from family, friends 
and other social relationships.  Findings from the present study support these findings as the perception of cancer 
risk was found to be influenced by a family history of breast or ovarian cancer and the participants’ personal 
experiences in dealing with their family history. The availability of both formal and social support was found to 
influence the perceived controllability of developing cancer.  
During the interviews, most of the participants reflected back on their experience of the PT process, how the 
pre-test counselling prepared them for receiving their result and how emotionally difficult it was for them to 
wait for their results. Participants tested in private typically waited between a week and two weeks to receive 
their results, while in most cases participants that had testing done through a public institution waited 
approximately six to eight weeks to receive their results. Most participants described the period of waiting for 




participants feeling that they were prepared to receive their results, some of them felt that in retrospect they 
may have benefitted from receiving additional support from a psychologist or someone from a mental health 
background while waiting to receive their results. This was particularly evident, but not exclusively, amongst 
participants who tested positive.  
“When I think back I feel many people can benefit if, say [my genetic counsellor] or whoever is on the 
other side, to say listen this is a hard week awaiting you, I recommend you just go and see a therapist or 
here are two names, that always helps, they work with people going through this. I think it will help a 
great lot with many people just to go and sit there and, you know, just help them go through, sort out 
stuff all the thoughts and emotions that go through because I went through that.” (P10) 
Hirschberg, Chan-Smutko & Pril (2015) have argued that at any point in the genetic testing procedure there are 
opportunities to identify individuals that are distressed and make appropriate psychology referrals.  Genetic 
counsellors need to evaluate an individual’s psychological functioning during the first pre-test counselling session 
and asses their ability to provide truly informed consent, as this may be impaired during periods of psychological 
distress. During pre-test counselling, patients should be allowed to explore the possible testing outcomes and 
anticipate thoughts and emotions about the possible results. By imagining the possible consequences of the 
testing results in the various facets of their life, they are better able to engage their coping mechanisms to try 
and modulate distress and to engage in preparatory planning (Hirschberg, Chan-Smutko & Pril, 2015). Although 
these suggestions have been made with affected individuals presenting for genetic testing in mind, similar 
considerations would apply for asymptomatic individuals undergoing predictive genetic testing.  
The delivery of genetic counselling plays an important role for at-risk individuals and their families during this 
time. Genetic counsellors are uniquely positioned to provide support to individuals undergoing PT and assist in 
guiding them through a complex decision making process to enable them to manage their risk (McCrea & 
McCutcheon, 2017).  
4.6.2 IT SHOULD HAVE BEEN ME  
PT for BRCA1 and BRCA2 mutations has been shown to have an impact on family functioning and relationships. 
A negative testing result can result in feelings of guilt, particularly in cases where other family members have 
been found to carry a BRCA1 or BRCA2 mutation. This is a phenomenon that is referred to as ‘survivor guilt’ 
(d’Agincourt-Canning, 2001; Douglas, Hamilton & Grubs, 2009).  
Some study participants expressed that they felt guilty because they had received a negative result. Despite 




they did not test positive, suggesting that it would have been fair to at least carry the mutation. The quotes below 
illustrate some of these responses:   
“I said I’m negative I know and I started crying. They asked me ‘why’ and I said because I was hoping I’m 
gonna have it.” (P4) 
“I wanted to be like my sister. I didn’t want her to go through it alone, I really didn’t want her to go 
through it alone.” (P4) 
“So, for me, yeah that was also very hard that, that’s why I just realised I must go test myself but I actually 
thought it should’ve been me. And I, I, I think I said to her at one stage I almost want to ask you for 
forgiveness is that it’s you and not me.” (P10) 
“Yeah, it wasn’t fun, it wasn’t fun and then I actually felt guilty when I was not. It should’ve been fair for 
me to at least have the gene or, just not have cancer.” (P10) 
Participant 12 expressed how she hadn’t accepted the fact that everyone else in her family that had been tested 
was found to carry the mutation and that she was the only one who tested negative.  
Interviewer: “And how did their positive results have an effect on you?” 
P12: “I don’t think I’ve actually accepted it yet. I don’t know why. I don’t think I’ve accepted it yet, like I 
don’t know.” 
Survivor guilt has been associated with profound effects on family relationships and difficulties in communication 
(Hallowell, et al. 2006; Huggins, et al. 1992). These individuals may find it difficult to communicate information 
about their mutation status to relatives that are mutation-positive and have difficulty with knowing how to 
support these relatives (Hallowell, et al. 2006; Goelen, et al. 1999). Conversely, there were also individuals that 
felt isolated as mutation carriers. These individuals felt that it was difficult to talk to family members that had 
tested negative. Participant 2’s quote below illustrates this: 
“So, initially that first six months it was really hard. And I couldn’t speak to anybody about it. It’s just, my 
sisters don’t have it, my parents and the older generation they just go about their life they’re not into 
checks and research and what not. But afterwards it’s just, now it’s just something on my list to do and I 




Family members who receive a positive test result can manifest a variety of strong emotions including shock, 
fear, anger and guilt. A positive test result can cause individuals to feel isolated within their family structures, 
especially if they find it difficult to communicate with other family members (Douglas, Hamilton & Grubs, 2009; 
Phelps, et al. 2007). This was particularly evident for participant 2 as she was the only sibling that received a 
positive test result. This concept of individuals testing positive and feeling isolated in their families is not unique 
to HBOC as it has also been described in families with HD and familial adenomatous polyposis (Douglas, Hamilton 
& Grubs, 2009; Duncan, et al. 2008).  
Some of the positive mutation-carriers that had children explained that they didn’t realise that their children 
could potentially be at risk and that once they had been informed of this possibility they felt distressed. This is 
demonstrated in the following quotes: 
“And for me one of the saddest things is that at some point I’m going to have to tell my sons and my 
daughter that potentially they have this.” (P2) 
“Initially I got a fright about that because I didn’t think about it. When I first got the result, I wasn’t 
thinking about my children and then it suddenly, you know, I was like oh my God my daughter, never 
mind the boys, my daughter, I mean and the boys.” (P15) 
“I know how [my mother] feels because my son is growing up, everything, you know, we’re feeling his 
breasts also now because he’s young but he can have it too. And he can give it too.” (P16) 
Several studies have shown that affected parents feel guilty or distressed about transmitting genetic mutations 
to their children and that they blame themselves for having put their children at risk of disease. This is not only 
seen in BRCA1 or BRCA2 mutation cases, but has also been documented with conditions such as myotonic 
dystrophy and cystic fibrosis (d’Agincourt-Canning, 2001; Faulkner & Kingston, 1998; Fanos & Johnson, 1995; 
Hallowell, et al. 2006).   
The participants’ post-test perceptions and experiences were highlighted in this theme. Upon reflection, some 
participants felt that they may have benefitted from additional psychological support while they were waiting 
for their result. Participants that received a positive diagnosis felt that they required additional support, both 
practical and emotional support, after receiving their result. Survivor guilt appeared to be a common 
consequence of receiving a negative result. The period following result delivery can elicit a variety of emotions 
and for some necessitate a call to action. The consequences of knowing one’s result are explored further in 




4.7 THEME 4 – CONSEQUENCE OF KNOWING  
The fourth theme addresses some of the post-test perceptions and attitudes of the participants after they had 
received their testing results. Despite receiving a negative test result, many participants felt that they had the 
same concerns and that their result did not mean that they were risk free. These findings will also illustrate the 
participants’ attitudes towards breasts and prophylactic intervention and address the power of knowledge.  
4.7.1 I’M NOT CANCER -RISK FREE  
The impact of genetic counselling content on health behaviour was investigated in the United States of America 
by Kelly, et al. (2015). The researchers were able to conclude that following genetic counselling and receiving a 
positive diagnosis, women were more likely to consider prophylactic surgeries and cancer screening, ovarian 
cancer screening especially. Interestingly, those that received genetic counselling followed by a negative result 
continued to opt for age-related population screening. It was postulated that the decision to continue cancer 
screening was likely as a result of genetic counsellors discussing the implications of cancer screening, highlighting 
the critical role of genetic counselling in genetic testing (Kelly, et al. 2015; Scott, et al. 2005). Similarly, the current 
study also showed that those receiving a negative test result also opted for continued cancer surveillance due to 
residual cancer worry. This is illustrated in the following quotes:  
“So, I readily go for, I do breast examinations and I ask the doctor to check because despite my results I 
have to be vigilant because we live in a time and a space, you know, you still have to be vigilant and 
take care of yourself.” (P1) 
“Because colon cancer is the other one that is rife in our family so obviously, that is something that you 
can’t let just park so we were encouraged that okay your risk is less for this one but just remember that 
that little bugger is still waving his hello flag on that side of the guy so just to be vigilant regarding 
that.” (P1) 
“So, I feel my risk has definitely lessened but at the rate that cancer is prevalent, especially breast 
cancer in women at the moment, there is no guarantee. I’m well aware that the risk is still there and ja, 
I know my risk is lessened but it’s still a risk.” (P3) 
 “I have the same concerns. I just know that I don’t have that weakness in my body. That’s the only 
thing I know I don’t have. But it is possible that my mother died of another cancer. So, and many other 




therefore I go for my tests just to be grateful that it’s negative or otherwise to pick it up if it’s there. No, 
I have the same risks. Yeah.” (P10) 
As can be seen, receiving a negative result does not exempt individuals from experiencing distress as there is still 
some remaining uncertainty. This was particularly evident in cases where there were other types of cancer in the 
family. Many participants explained that receiving a negative result did not mean that they were free from any 
cancer risk and that based on their family history they felt there would always be some residual risk. The above 
quote by participant 10 illustrates how the PT result simply excluded one type of cancer but it was still important 
to remain vigilant for other types of cancer. She felt that her negative result did not reduce her risks for 
developing cancer.  
There are often conflicting emotions of relief, guilt and fear, amongst others, associated with receiving a negative 
result. Some studies have shown that these individuals will continue to have some residual cancer-related worry 
and seek out additional cancer screening, particularly at those younger ages (Hirschberg, Chan-Smutko & Pril, 
2015; Macrae, et al. 2013). In keeping with the findings by Hirschberg, Chan-Smutko & Pril (2015), this highlights 
the importance of ensuring that individuals have an accurate perception of their risk and emphasising that the 
risk of developing cancer is not binary, not only during the PT process but also after receiving their results. 
4.7.2 IT’S THE DISFIGUREMENT  
Concerns have been raised regarding the psychological harm of PT for BRCA1 and BRCA2 mutations and 
undergoing prophylactic surgery. Risk-reducing strategies can influence levels of anxiety and psychological 
distress, as well as overall physical health (Harmsen, et al. 2015; Stan, et al. 2013). RRBM is a visibly disfiguring 
and permanent intervention that has the potential to affect an individual’s sexual functioning and body image 
(Harmsen, et al. 2015; Meijers-Heijboer, et al. 2000).  
Three of the six study participants that tested positive for a familial BRCA1 or BRCA2 mutation had undergone 
prophylactic surgery in an attempt to manage their risks. Two participants underwent a RRBM and one 
participant underwent a BSO. All three participants expressed that they were relieved that their risk following 
prophylactic surgery was reduced. The remaining mutation-positive individuals had opted for regular surveillance 
as a means to manage their risk. Of the three participants that opted for regular surveillance, one participant 
was male and the remaining female participants chose not to have surgery because they were concerned about 
the disfigurement of having their breasts removed. Harmsen et al. (2015), identified factors influencing female 




strong family history of cancer and increased cancer-related distress. These were the same factors identified in 
the present study.  
One of the greatest concerns raised by the study participants with regard to prophylactic intervention is that 
unlike a prophylactic hysterectomy or BSO which is ‘internal’ and not physically visible to the outside world, the 
RRBM was referred to as being ‘external’ and that the physical disfigurement can be seen. This is consistent with 
what is described in some literature which shows that females that are mutation-positive are more likely to opt 
for a prophylactic BSO when compared to prophylactic RRBM (Johns, et al. 2017). The majority of female 
participants, regardless of their mutation status, expressed fears about feeling like less of a woman and that their 
breasts were central to how they identified themselves and how they felt their husbands identified them.  
“So, ja, I was scared about feeling like less of a woman and then the other thing is the ovarian cancer 
where they say you can have your, have a what, a hysterectomy but then you go into menopause and I’m 
like hell no, you know. I just wasn’t ready to do that, I don’t think I’ll ever be ready to do it unless I need 
to. It’s like if you have a bad tooth, you first try and fill it before you pull it out.” (P2) 
“Yes, I mean as a woman to not have breasts, my husband loves breasts, like I think he’s obsessed with 
breasts, you know. So, imagine if I didn’t have breasts.” (P2) 
“I would never be able to, I won’t have nipples, ja. So, that kind of, that kind of threw me.” (P15) 
Importantly, in addition to participant 15’s quote above, she explained how the decision to have a prophylactic 
BSO was an easy one because it was not something that would be outwardly visible. The thought of not having 
breasts and specifically nipples is what influenced her decision to not have a RRBM and to opt for regular breast 
surveillance instead.  
Participant 13 explained how, as a male, his concerns were centred around the disfigurement of breast surgery. 
He recalled how difficult the experience was for his male relatives who had undergone mastectomies following 
a diagnosis of breast cancer and that prior to learning about his family history he had always assumed that breast 
cancer was only associated with being female. 
“I think it’s not so much for me, it’s not saying oh well I have breast cancer, I think it’s the disfigurement 
of surgery, the cosmetic side of it and then people looking at you and going, it’s just an odd place to have 
scars if you’re a man, I think, and if it’s uncovered. I mean, my dad’s got his scars and it’s not too 




Despite the fears associated with body image, the two mutation-positive female participants who had opted for 
having a RRBM felt strongly about their decision and did not regret the choices that they had made. For these 
participants, the cancer-related worry that was associated with not having the surgery far outweighed their fears 
about their change in body image. This is illustrated in the following interview excerpts:  
“And I was, you know, I was lucky, I was done with that tissue, I’ve been a mom, I’ve breast fed, I’ve done 
it all and not to say that I wouldn’t have looked at some form of augmentation later on anyway.” (P7) 
“I was petrified for this, I was petrified, but I would rather like take something out that could go bad and 
that for me was just like my approach and how I just felt about it.” (P7)  
This is in agreement with previous literature which found that women who opted for a RRBM, after receiving a 
positive PT result and adequate counselling, were relieved from the fear of developing cancer and rarely 
expressed regret regarding their decision (Meijers-Heijboer, et al. 2000). The two mutation-positive female 
participants who opted for RRBM expressed that the decision to not have a prophylactic BSO was based on the 
fact that they were concerned about having to go through menopause at a young age. Following a 
recommendation by her gynaecologist, one of these two participants had opted to have her fallopian tubes 
removed as an additional prophylactic measure.  
4.7.3 EMPOWERED BY KNOWLEDGE  
Most of the participants felt that the PT process had a positive impact in that it allowed them to increase their 
knowledge and understanding about what it means to be a BRCA1 or BRCA2 mutation carrier and it provided 
them with an opportunity to receive the correct information. They felt empowered by the knowledge that they 
had received as a result of undergoing PT.  
“So, we realised that, you know, we’ve got something that our aunts and grandparents didn’t have and 
that’s the power of knowledge.” (P1) 
 “That’s the thing, you know, if you, I mean I understand we don’t all know how or when or what we are 
going to be, what we could get with different cancers or this or that, heart disease, but if you can find out 
what you are predisposed to, it’s about having that knowledge, knowledge is power, like for me that’s 
what I felt, I felt really strongly about.” (P7)  
These findings are similar to those identified in previous studies in which the perceived advantages of receiving 




improved awareness about their breasts and feeling more in control about managing their risks (Brunstrom, 
Murray & McAllister, 2016; Hamilton, Lobel & Moyer, 2009).  
Some participants felt that by knowing their mutation status and their cancer-related risks, they could better 
manage their risks and take precaution where necessary. For those that tested negative, they felt that they could 
live their lives without worrying about whether they were at risk.  
“I feel much better, I feel happier because I don’t have to take that extra precaution and I can actually 
live now because I’m obviously young still and the thought of me, if I did have it, removing my breasts or 
my ovaries for example. I mean, I obviously want to have children one day and that was quite scary, so 
yeah. It helped me a lot.” (P12) 
“So, I feel lucky that I know because I’ve been able to take steps and I’m still taking steps now” (P15) 
Individuals knowing that they are potentially at risk for HBOC, based on information provided by family members, 
may experience fear and uncertainty about their personal risks, but the knowledge of one’s mutation status and 
risk values can be empowering and a beneficial outcome of doing the test. Individuals potentially at risk are likely 
to seek out advice from genetic counsellors or healthcare professionals in order to improve their understanding 
of HBOC, determine their risks and take action to prevent cancer or manage their risks, where necessary 
(Brunstrom, Murray & McAllister, 2016; Crotser & Dickerson, 2010).  
Many participants explained that by going through the PT process, they experienced a change in their family 
dynamics. It forced individuals to have difficult conversations and allowed them to open up about their family 
history. Many described that their families grew stronger as a result, regardless of the outcome of the testing. 
This is illustrated in the following interview excerpts:  
“That’s why I said it forced people to have difficult conversations which is a good thing in our … 
community, to put it that way. Everything is always under the wraps in the big … we don’t speak about 
illness ever.” (P1) 
“And let’s be honest, we are much stronger than ever before. I’m feeling now like we much closer, we 
much open. The bond now is even stronger.” (P4) 
“The main results for me is that we became much, much closer as a family and that we learn something, 
something very valuable and that we can share with other people and I think no one can take that away 




The discovery of a cancer-predisposing mutation in a family has previously been shown to have a positive effect 
on some family relationships. For some families, it may serve as a means to engage in conversations about cancer 
or to allow for increased contact between family members (Douglas, Hamilton & Grubs, 2009). Conversely, in 
some cases individuals may feel isolated within their families or feel that they have been forced to pursue testing. 
Individuals who receive a positive test result may find it difficult to disclose their results to family members who 
are still at risk or have received a negative test result (Van Riper & McKinnon, 2004). In a study by d’Agincourt-
Canning (2001) which explored the experiences of genetic risk, the research participants found that genetic 
testing allowed for the strengthening of relationships amongst family members due to the importance of the 
information that had been disclosed. Similarly, McInerney‐Leo, et al. (2005) reported that there was a perceived 
improvement of family cohesiveness, regardless of whether individuals had chosen to pursue PT.  
In summary, the participants’ post-test perceptions and the consequences of knowing one’s result are explored 
in the fourth theme. Participants in this study felt that a negative test result did not mean that they were free 
from risk for developing cancer and that there was some remaining uncertainty. Concerns were raised about the 
psychological and physical harms associated with prophylactic intervention and particularly the visible, physical 
disfigurement of a RRBM. Overall, participants felt that they were empowered by knowing their mutation status 
and they could better manage their risks and take precaution where necessary and some experienced a positive 
change in their family dynamics. However, the need for support throughout the PT process appeared to be a 
recurrent theme, regardless of the testing outcomes. The role of support in the PT process will be explored in 












4.8 THEME 5 – SUPPORT AND ITS ROLE IN THE PREDICTIVE TESTING PROCESS 
In this study, support has been identified as an overarching theme. Support from healthcare providers, from 
families, the need for additional practical and emotional support following a positive diagnosis and the need for 
support in the period leading up to receiving their results. Several participants expressed their gratitude for the 
support that they had received throughout the PT process, not only by the healthcare providers but also by their 
family members. The following quotes illustrate how the study participants felt supported by the healthcare 
providers throughout the PT process: 
“So, it’s all thanks to you guys, for helping, for assisting us. You guys were there supporting us, the family, 
the counselling. I mean from the beginning of this process, it really was a big help to the family. If it wasn’t 
for you guys we would have been lost. If it wasn’t for the counselling, I don’t know. I don’t think we would 
have survived it.” (P4)  
“They were very sympathetic, I was like in tears and you could see that, you could see the concern and 
you could actually feel the love man and the support when they talk to you. They didn’t just talk to you, 
you could see that they really cared and I think that made me feel more at ease because I was very 
supported.” (P9) 
The need for additional social and emotional support was raised by several participants, both prior to receiving 
their results as well as following result delivery. The need for emotional support following result delivery was 
raised almost exclusively by positive mutation carriers, however there was one participant who received a 
negative result but felt that there could have been additional support following result delivery:  
“And then what I also wanted, suggestions or whatever, they could just every year at least just to keep 
us positive phone us and find out how you feel. I mean, but now after the test and the results it was just 
quiet. Nobody phone back and say do you still remember you came for this test and how do you feel, are 
you still okay and all that, but they don’t.” (P11) 
Mutation-carriers felt that they could benefit from increased support and follow up as well as continued 
interaction with healthcare providers following result delivery: 
“And then afterwards, once the result is out, if somebody could speak to you. Like in my case, I had other 
things going on in my mind, then to say okay, you know, maybe this is what you could do or look into, or 




“I even phoned my medical aid. I said to them look, you know like you have a cancer program, what do 
you have to support somebody in my situation? They say no you can only register on the cancer program 
once you have cancer, you see. So, that was another door closed. There wasn’t somebody that I could 
speak to there, which is wrong.” (P2) 
“Maybe having a little bit of a support with regard to the psychology aspect. Also, maybe as a person 
who’s been through it, if you could get matched up with someone perhaps within the same so socio-
economic group, or demographic, or maybe not, I don’t know, there’s different people and we all react 
differently.” (P7) 
Men and women that undergo predictive genetic testing for hereditary cancer syndromes may experience 
psychological distress during the time that they are going through the process of testing or following 
identification of their mutation status, differently (Hirschberg, Chan-Smutko & Pril, 2015). Individuals that are 
said to be ‘at-risk’ are asymptomatic mutation carriers that are aware of the potential of a disease becoming 
reality. As a result, these individuals occupy a unique position within the healthcare system, redefining what it 
means to be a patient. Given that the risk values are not absolute and that there is variability in the penetrance 
estimates, they are constantly confronted with the possibility of future suffering. These individuals often find 
themselves in a position where they are neither healthy nor affected, but rather a hybrid of the two (Scott, et al. 
2005).  
In addition to participant 2’s quote above, she explained how she had subscribed to overseas newsletters and 
joined forums which support unaffected mutation carriers and that after extensive research she could not find 
any similar services in SA. Similarly, the following participants explained how they would have benefitted from 
talking to individuals that have been in a similar position:  
“So, and you’re dealing with human beings, you know, and a hell of a lot emotion and is specially for a 
female and maybe their kids haven’t had kids, I don’t know, there is a lot to it all, so it’s hard to put a box 
and say this is how they must be treated, but as I say, maybe having a little bit of a support with regard 
to the psychology aspect but also maybe at person who’s been through it, if you could get matched up 
with someone perhaps within the same so socio-economic group, or demographic, or maybe not, I don’t 
know, there’s different people and we all react differently.” (P9)  
“The questions I had is like, somebody that goes through it, I want to speak to somebody like that. A 




you feel. It’s not that. You want to know, the stuff I wanted to know are if it’s sore, what will I expect 
afterwards, did you have nausea, what’s going to happen, are you depressed.” (P16)  
The lack of desired support for mutation carriers has been illustrated in the above comments. As cancer risk 
assessment and PT for hereditary cancer syndromes becomes more readily available, it is essential that service 
providers meet the mental health needs of these at-risk, but otherwise unaffected individuals (Hirschberg, Chan-
Smutko & Pril, 2015). Genetic counsellors, in particular, are well suited to provide pre-test and post-test 
counselling in a supportive environment, as well as assisting patients in making sense of what their results mean 
for them and their family members and addressing the emotional impact throughout (Arning, et al. 2015). In SA, 
however, there are only approximately 25 practicing genetic counsellors which means that this service is also 
largely offered by other healthcare professionals (Ormond, et al. 2018). It is therefore important that all 
healthcare professionals offering this service are able to identify individuals that require additional psychosocial 
and practical support and make the necessary referrals or recommendations.  
4.9 CHAPTER SUMMARY 
In summary, the study results were presented. The results were discussed and linked to the aim and objective of 
the study. Following analysis of the interview data five themes were identified. These themes were explored 
through interview excerpts and were supported by published literature. In the final chapter, the conclusions of 
the study are presented, as well as the strengths and limitations of the study. Recommendations will be 















CHAPTER 5: CONCLUSIONS, STRENGTHS AND LIMITATIONS OF THIS STUDY AND 
RECOMMENDATIONS FOR FUTURE RESEARCH 
5.1 CHAPTER INTRODUCTION  
This chapter will include (1) a summary of the relevant findings of the research, (2) the researcher’s personal 
reflection, (3) a discussion of the strengths and limitations of this study, (4) practical implications of this research 
and (5) recommendations for future research.  
5.2 CONCLUSIONS  
This qualitative research study aimed to explore the experiences of individuals undergoing PT for HBOC in the 
Western Cape, SA and their perceptions of the PT process. By investigating these individuals’ perspectives and 
experiences of undergoing PT for HBOC, this research aimed to understand what factors influence an individual’s 
decision to pursue PT, how effective the pre-test counselling is in preparing them to receive their result and their 
post-test perceptions. Fifteen individuals that underwent PT for a familial BRCA1 or BRCA2 mutation were 
interviewed in this study. The interviews were transcribed verbatim and thematic analysis was performed using 
the framework approach. Five themes were identified from the participants’ accounts as they related to the aim 
and objectives of this study.  
The first theme focused on the pre-test period. In particular, the influence of their family history of cancer and 
the factors influencing their decision to pursue PT. It was found that participants mainly chose to have testing 
because they felt a responsibility to their families and their children or future children to know their risk and 
manage it where possible. Some participants chose to be tested out of a sense of duty to their family members 
affected by breast or ovarian cancer, or both, or because their family members were being tested at the same 
time. Experiencing a family member being diagnosed with cancer or the loss of a family member resulted in 
increased cancer-related distress amongst participants. Most participants felt that their family history of cancer 
increased their risk perception and influenced their decision to test.  
The second theme identified addresses how the participants felt the pre-test counselling prepared them to 
receive their results. While most participants felt that the information provided during pre-test counselling 
helped prepare them to receive their result, there were some participants that felt that while the pre-test 
counselling was informative, it wasn’t what prepared them to receive their results. Some participants felt that 
the support from their family and their experiences in dealing with a family history of cancer is what prepared 
them for their results. Some participants felt that their perceptions of the pre-test counselling may have been 




It was found that some participants felt guilty about receiving a negative result. Survivor guilt was evident 
amongst individuals who were tested concurrently with other family members and amongst those who had a 
living relative diagnosed with breast or ovarian cancer. It was also found that some individuals who tested 
negative felt that their result did not exempt them from experiencing cancer-related distress and that based on 
their family history they were still at risk for developing cancer. Some individuals experienced shock and grief by 
learning that their children could also be at risk.  
One of the greatest concerns raised by the study participants with regard to prophylactic interventions was the 
disfigurement of a RRBM. Most female participants, regardless of their mutation status, expressed fears about 
feeling like less of a woman and that their breasts were central to how they identified themselves and how they 
felt their husbands identified them. One male participant felt that it was an odd place for a male to have scars. 
Despite these fears, three female participants had proceeded with a RRBM and did not regret their decision.  
Overall, most participants felt empowered by the knowledge of their mutation status and that they were able to 
better manage their risks and take precaution where necessary or live their lives without worrying about whether 
they were at risk. Some participants explained that by going through the PT process, they experienced a positive 
change in their family dynamics and that there was improved family cohesiveness.  
The need for additional support, both practical and emotional support, was particularly evident amongst 
mutation-carriers. Mutation-carriers need to make difficult decisions about how to best manage their risk going 
forward, deciding between surveillance and prophylactic options. Concerns were raised about the lack of a 
holistic service geared towards supporting individuals who are found to be mutation carriers, particularly those 
that chose surveillance over prophylactic intervention. Some participants felt that they would have benefitted 
from formal psychological support, while others felt that they would have preferred to talk to someone that had 
been through a similar experience.  
In conclusion, the findings of this study indicate that there is a need for additional support both throughout the 
PT process, as well as following result delivery irrespective of the setting in which the service is provided. While 
the pre-test counselling content appears to be sufficient in facilitating informed decision-making, individuals are 
not always emotionally prepared to receive their result and to deal with what their result means in the context 
of their unique situation. In SA, there are no formal guidelines or testing protocols in place for individuals 
undergoing PT for HBOC, meaning that the PT process, including the counselling content and provision of support 
before and after result delivery, may vary across the institutions and genetic counsellors that offer this service. 
In other countries, such as Belgium, there are established PT protocols for HBOC which include a psychological 




found in Belgium, it is evident that the individuals in this study have support needs beyond what is being offered 
to them or what works best for them. The participants clearly communicated a need for more emotional support 
and this should be addressed in our local setting.  In addition, they communicated a need for informal support 
such as support group. This has been highlighted by several studies. These have highlighted the benefits of 
support groups and organisations that are focused on providing support for individuals that receive a positive PT 
result for HBOC. These less formal support structures are able to connect individuals share similar experiences 
(Hoskins, Roy, & Greene, 2012). 
This need for further support could be addressed by adapting current PT protocols. While these findings do not 
suggest that there is a need for a uniform PT protocol for all individuals undergoing PT for HBOC in SA, healthcare 
providers in this setting need to be able to recognise where additional support is required and make 
recommendations where necessary. As seen in the present study, psychological challenges can arise throughout 
the process, from decisions to pursue testing, to making decisions based on the outcomes of the PT results. Based 
on the findings of this study and literature by Hirschberg, Chan-Smutko & Pril (2015), the guidelines in table 5 
below have been proposed to assist genetic counsellors and healthcare providers offering PT for HBOC in 



















Table 5: Proposed pre-test and post-test counselling consultation guidelines 
Pre-test counselling consultation  Post-test counselling consultation  
 Explore why the patient is there and their reasons for 
wanting to pursue PT 
 Obtain a comprehensive family history taking note of 
any children/other relatives that may be at risk  
 Provision of information on HBOC and cancer risks 
associated with the familial mutation 
- Clarify that this is a genetic predisposition and 
not a test to determine if the individual will 
develop cancer or not 
 Encourage individual to explore possible testing 
outcomes and what they would do if they tested 
positive or negative 
 Discuss management options if positive (surveillance 
and risk-reducing surgery) 
 Discuss possibility of life insurance discrimination  
 Explore psychosocial impact of positive and negative 
result 
 Explore how the result would affect future decision-
making and planning 
 Explore their support system  
 Discuss information dissemination/risk communication 
in family 
 Provide emotional support 
 Discuss testing approach and practical arrangements 
(turn-around time, plan for result delivery, etc.) and 
offer support during waiting period  
 Decide on whether they want to proceed with testing or 
delay it  
 Consider referral for additional psychosocial support in 
the following cases: 
- Increased baseline distress or anxiety  
- History of depression or mental illness  
- Elevated risk perception  
- Complicated grief  
- Individuals with children  
- Loss of a relative to hereditary cancer  
 Provide written information  
 Plan for follow-up 
Individuals who receive a negative test result:  
 Discuss screening for early detection 
according to general population 
recommendations  
 Consult family history to determine if 
other family members should be tested 
and if/how they need to be notified  
 Consider referral for additional 
psychosocial support in the following 
cases: 
‐ If individuals display signs of 
depression  
‐ Survivor guilt  
 Open invitation for follow-up  
Individuals who receive a positive test result: 
 Re-discuss risk implications (cancer and 
familial risks)   
 Provide emotional support  
 Discuss management options  
 Refer to breast specialist and 
gynaecologist to discuss surveillance 
and/or risk-reducing surgery options and 
plan for follow up  
 Provide summary letter  
 Consult family history to determine if 
other family members should be tested 
and if/how they need to be notified  
 Consider referral for additional 
psychosocial support  
 Consider referral to support groups 
(including overseas if none available 
locally)  





Although some of the findings in this study are similar to those identified in previous international literature, the 
outcomes of this study have provided valuable insight into the perspectives and experiences of individuals 
undergoing PT for HBOC, which has not yet been explored in this local setting. The findings of this study are able 
to potentially impact the services that are provided to individuals undergoing PT for HBOC. The strengths and 
limitations of this study are listed below. 
5.3 STRENGTHS OF THIS STUDY  
 This study is the first to employ qualitative research methods to explore the perspectives and 
experiences of individuals undergoing PT for HBOC in a South African setting.  
 The use of a semi-structured interview guide, including open-ended questions, encouraged participants 
to answer questions openly and without restriction.  
 Several of the participants felt that despite the emotional nature of their experiences, the interview 
process allowed them to share their story, an opportunity that many of them hadn’t done before, and 
found it to be helpful and therapeutic.  
 The use of purposive sampling aided in the recruitment of individuals that highlighted novel issues that 
are specific to the selected settings in the Western Cape, and may be relevant to other settings in SA and 
countries that provide the same service. 
 Owing to the fact that there are small numbers of genetic counselling students in SA conducting 
qualitative research pertaining to genetic disorders, these findings are valuable in contributing to the 
growth of this field locally.  
5.4 LIMITATIONS OF THIS STUDY  
 While the aim of undertaking qualitative research methods was for practical growth of the researcher, 
this was the researcher’s first attempt at qualitative research and interviewing. The consequence is that 
there was variability in the quality of the interviews.  
 All of the interviews were conducted in English. Not all of the participants’ first language was English and 
despite being offered to include an interpreter, they chose to have the interview conducted in English. 
The participants whose first language is not English may not have been able to express themselves fully.  
 There may have been some ascertainment bias as the perspectives and experiences of those unwilling 
to participate or those that are less communicative are not included. This is commonly associated with 
purposive sampling. 
 One of the limitations of recruiting individuals from both the public and private sectors is that there is a 




the private sector. Every attempt was made to have adequate representation of participants from both 
groups. However, the main objective was to obtain as comprehensive a view on the PT process for HBOC 
as possible in the Western Cape and not to make comparisons between the two sectors.  
 The fact that the researcher is undergoing genetic counselling training at one of the institutions sampled 
in this study may have affected the responses obtained from individuals sampled from the institution.  
5.5 PRACTICAL IMPLICATIONS OF THIS STUDY  
Certain aspects of this research may have future practical implications and are recommended below:  
 Increased provision of formal emotional support for participants that are undergoing PT for HBOC, prior 
to result delivery and once the results have been delivered, as it is important that participants feel 
supported throughout the PT process and post-delivery of results. 
 Establish a formal referral protocol which ensures that mutation-positive individuals are referred to the 
appropriate specialist services for further management. This will allow them to feel secure in knowing 
that they are taking the necessary steps to manage their risk in an informed way. 
 The formation of a support group for mutation carriers which would create a forum for mutation carriers 
to openly discuss issues or concerns that they have, to share experiences and to gain insight from 
individuals that have been in a similar position.  
 It is important that clinicians and genetics healthcare professionals providing this service and supporting 
mutation carriers understand the perspectives and experiences of individuals undergoing PT for HBOC, 
in order to meet the specialised needs of these individuals and to work towards improving service 
delivery.  
 There is evidence from this research to suggest that guidelines should be drafted with recommendations 
to assist with the provision of additional psychosocial support throughout the PT process.   
5.6 RECOMMENDATIONS FOR FUTURE RESEARCH  
The following recommendations have been made in an attempt to guide future research: 
 Although it would possibly be difficult, it would be beneficial to explore the experiences of individuals 
that have a family history of HBOC but choose to decline to pursue PT and the reasons for doing so. 
 Exploring the perspectives and experiences of individuals undergoing PT for HBOC between the ages of 
18 and 25 years. Several international studies have highlighted that young adults are particularly 




partnerships and possibly becoming parents. Having one participant in this age group was not sufficient 
to evaluate the impact of presymptomatic testing for HBOC in young adults.  
 Exploring the perspectives and experiences of individuals that undergo PT for mutations in genes other 
than BRCA1 and BRCA2, which are associated with an increased risk for developing breast cancer. 
 The financial implications of PT did not appear to be of significant concern amongst the individuals 
sampled in this study. Interestingly, concerns were raised about the financial implications of increased 
surveillance and prophylactic intervention amongst mutation-positive participants. Future research 
should explore this topic in a local setting and make comparisons between the public and private sectors.  
 Explore the topic of insurance discrimination amongst individuals in SA that have received their PT result.  
5.7 CHAPTER SUMMARY  
In this chapter, conclusions have been made based on the research outcomes, the strengths and limitations of 
this study have been presented, as well as the practical implications of the research and recommendations for 
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APPENDIX A: SOCIO-DEMOGRAPHIC QUESTIONAIRRE 
Socio-Demographic Questionnaire  
To be completed by the participant: 
1. Name:  
2. Age:  
3. Gender (please circle): Male/Female  
4. Are you in a stable relationship (please circle): Yes/No 
5. Do you have any children? If yes, how many:  
6. Country of origin:  
7. Employment status (please circle): Employed/Unemployed     
If employed, what work do you do? 
8. Highest Education level (please circle): Primary school/high school/tertiary education/none 
To be completed by the researcher: 
9. Mutation status (if optionally provided by participant):  













APPENDIX B: INTERVIEW GUIDE  
 Tell me about yourself and your experiences with cancer 
- Prompts: 
o Which of your family members were affected by breast or ovarian cancer?  
o How old were they when they were diagnosed? 
o How old were you when they were diagnosed?  
o How did their diagnosis impact you?  
 Tell me about your emotional/social support system 
- Prompts: 
o How did you family members feel about your decision to undergo predictive testing for 
HBOC? 
o Were there people that you chose not to tell or couldn’t tell?  
 Why was it important to you whether you carried the mutation? 
- Prompts: 
o What factors influenced your decision to undergo predictive testing?  
o Do you feel that you are independent or do you rely on the advice or guidance of friends to 
family members? 
 How do you feel now that you know your result? 
- Prompts: 
o What do you think the main advantages and disadvantages are of knowing your predictive 
testing result?  
 Tell me about the process that you underwent 
- Prompts: 
o What worried you the most about not knowing your mutation status? 
o What medical professionals were involved in this process?  
o How do you think the process prepared you to receive your result? 
o How do you feel your concerns were addressed?  
o What was the result that you were expecting? 
o How do you feel about your risk for developing breast or ovarian cancer? 
o What socio-economic factors or barriers do you think were present at the time that you 
were undergoing predictive testing? 





o Additional sessions  
o Psychologist  
 What was the actual information that was conveyed to you? 
- Prompts: 
o What was said about the implications of the results? 
o Do you feel that you were sufficiently informed? 
 What worries or concerns did you have during this process?  
- Prompts: 
o What did you do or who did you speak to about your worries or concerns?  
o How have your concerns changed since knowing?  
 How did this process prepare you for receiving your results? 
- Prompts: 
o Do you think anything could have been done differently during this PT process? 
 Have you told anyone about your mutation status? 
- Prompts: 
o How did you feel about telling them your mutation status? 

















APPENDIX C: INFORMATION SHEET FOR PARTICIPANT RECRUITMENT 
Participant Information Sheet 
___________________________________________________________________________________________ 
STATEMENT BY PARTICIPANT 
I, _______________________________________________ confirm that: 
1. I have been invited to be involved in the above-mentioned research project which has been initiated 
through the division of Human Genetics at the University of Cape Town. I understand that 15-20 other 
adult participants will be involved in the study and that my name and other personal information will 
not be discussed with the other participants or with anyone else not involved in the study.  
 
2. I understand that the objective of the study is to understand how individuals, in the Western Cape 
Province of South Africa, perceive and experience the predictive testing procedure for hereditary 
breast and ovarian cancer (HBOC). 
 
3. I understand that the interview will take place in a private setting at Groote Schuur Hospital (GSH), 
Tygerberg Hospital, a private genetic counselling practice (PVT) or telephonically, on a pre-scheduled 
date and time that is agreeable for me, the participant, and the researcher.  
 
4. I understand the interviews will take approximately 60 minutes. Should it be required that the 
interview run for longer than this allocated time, I, the participant, would be invited to reschedule at 
my earliest convenience to continue the interview.  
 
5. I understand that I voluntarily choose to participate in this study and if I choose to no longer continue 
that my decision will not in any way affect the health care services I currently receive at GSH, Tygerberg 
Hospital or UCT Private Academic Hospital. 
 
6. I understand that the questions may cause emotional reactions and that I may choose not to answer 
any questions if I do not wish to do so. I understand that I may decide to stop with the interview 
process at any point if I feel uncomfortable or too emotional and that this will not impact on my pre-
existing and future healthcare in any way. A genetic counselling session can be arranged if I would like 





7. I understand that my involvement in the study may contribute to health care professionals having a 
better understanding of the impact of predictive genetic testing for HBOC on individuals in the South 
African public and private healthcare systems. This information will assist health care professionals in 
understanding how various medical, counselling and therapeutic options can be adjusted accordingly 
to the needs of these individuals.  
 
8. I understand that all information collected will remain confidential and will be used for research 
purposes only. 
 
9. I understand that the interview will be recorded for research purposes. All audio recordings will be 
safely stored under lock and key and information stored on a password-protected computer. I 
understand that only the researcher, her supervisors and examiners will have access to the data. All 
recordings will be destroyed upon completion and publication of this study and all identities will 
remain anonymous.  
 
10. I understand that the interview will take place in English and that the researcher will be administering 
the interviews herself and if I do not feel comfortable communicating in English and require a 
translator, a suitably trained individual will be used to translate the interview and supplementary 
documentation.  
 
11. I understand that this study has been approved by the registered Human Research Ethics Committee at 
the Faculty of Health Sciences at the University of Cape Town. I have been given contact details should 
I wish to contact the committee about how I was treated as a research participant.  
 
12. I have the researchers contact details in the event that I would like to contact her regarding further 
questions about this study. 
 
13. _____________________________ has explained the information of this study in English or in 
_____________________________ through the use of a suitably trained translator and I understand 






APPENDIX D: PARTICIPANT CONSENT FORM  
Participant Consent Form 
___________________________________________________________________________________________ 
I hereby declare that I have voluntarily agreed to participate in the above-mentioned research study and that 
the interview can be audio-recorded.  
Signed at: 
 
(Address of venue)  __________________________________ on __________________________ 2018.  
 
_____________________________                        __________________________ 
Participant Name                                 Witness Name 
 
_____________________________                       ___________________________ 
Participant Signature                                                Witness Signature  
_____________________________________________________________________ 
 
If you have any questions regarding your rights as a research participant, please contact the Human Research 
Ethics Committee at the Faculty of Health Sciences of the University of Cape Town.  
Professor Marc Blockman (Chairperson of the Human Research Ethics Committee): 
Tel: (021) 406 6496 
If you have any questions regarding the research or the research procedure, please contact the researcher or 
her supervisor: 
Monica Rodrigues Araujo (Researcher): Tel: 083 406 2350 | Email: arjmon001@myuct.ac.za  





APPENDIX E: ETHICAL APPROVAL  
 
